dupilumab vs Rademikibart

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanism: IL-4R-alpha · full Chronic Obstructive Pulmonary Disease pipeline

dupilumab · Dupixent

Marketed by Regeneron Pharmaceuticals and partners

Approved in Chronic Obstructive Pulmonary Diseasemonoclonal antibody
Partial signal

NCT03930732 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial of 939 participants, and its primary clinical endpoint was met: dupilumab significantly reduced moderate or severe COPD exacerbations over 52 weeks. The registry does not report the power or sample-size calculation needed to establish that the trial was adequately powered, so the evidence is graded as moderate rather than strong.

Next expected readout: July 2028 · NCT07587658 (registry estimate)

Reported efficacy

Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-week Treatment Period (Baseline (Day 1) to Week 52): Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-week Treatment Period (Baseline (Day 1) to Week 52): Placebo 1.295 Exacerbation per participant-year (95% CI 1.048 to 1.6) | Dupilumab 300 mg q2w 0.859 Exacerbation per participant-year (95% CI 0.699 to 1.057) (met)

Result source: NCT04456673

Rademikibart

Developed by Connect Biopharma and partners

Phase 2 in Chronic Obstructive Pulmonary Diseasemonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT07705737 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointdupilumabRademikibart
Moderate or severe exacerbations, annualised rate0.8 vs 1.0−0.2 vs placebo300 mg q2w · wk 52 · n 468NCT03930732
1 other result
  • 0.9 vs 1.3 300 mg q2w · wk 52 · n 470 · Phase 3 · primary NCT04456673
—Not reported
Trough FEV1, change—Not reported—Not reported
SGRQ total, change-9.7 vs -6.4−3.4 vs placebo300 mg q2w · wk 52 · n 456NCT03930732
1 other result
  • -9.8 vs -6.4 300 mg q2w · wk 52 · n 350 · Phase 3 · secondary NCT04456673
—Not reported
TDI focal score—Not reported—Not reported

Moderate or severe exacerbations, annualised rate

dupilumab
0.8 vs 1.0−0.2 vs placebo300 mg q2w · wk 52 · n 468NCT03930732
1 other result
  • 0.9 vs 1.3 300 mg q2w · wk 52 · n 470 · Phase 3 · primary NCT04456673
Rademikibart
—Not reported

Trough FEV1, change

dupilumab
—Not reported
Rademikibart
—Not reported

SGRQ total, change

dupilumab
-9.7 vs -6.4−3.4 vs placebo300 mg q2w · wk 52 · n 456NCT03930732
1 other result
  • -9.8 vs -6.4 300 mg q2w · wk 52 · n 350 · Phase 3 · secondary NCT04456673
Rademikibart
—Not reported

TDI focal score

dupilumab
—Not reported
Rademikibart
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Rademikibart: no structured comparison results are available for Chronic Obstructive Pulmonary Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. dupilumab: 4 of 4 rows · Rademikibart: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricdupilumab
Dropout rate
6%300 mg q2wa
NCT03930732 · Phase 3
show 1 more result
8.9%300 mg q2w
NCT04456673 · Phase 3
Discontinued due to AEs
1.5%300 mg q2wa
NCT03930732 · Phase 3
show 1 more result
3%300 mg q2w
NCT04456673 · Phase 3
Serious AEs
13.9%300 mg q2wa
NCT03930732 · Phase 3
show 1 more result
13.9%300 mg q2w
NCT04456673 · Phase 3
Most frequent reported AEs
300 mg q2wa
nasopharyngitis 9.6% (placebo 9.6%)
headache 8.1% (placebo 7%)
upper respiratory tract infection 7.9% (placebo 9.8%)
NCT03930732 · Phase 3
show 1 more result
300 mg q2w
covid-19 9.6% (placebo 7.8%)
headache 7.9% (placebo 6.3%)
nasopharyngitis 6.8% (placebo 6%)
NCT04456673 · Phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

dupilumab

Moderate or Severe Exacerbation Rate Annualized 0.776 vs 1.01 placebo per year @ 52wk300 mg q2w
event rate · per year
NCT03930732 · Phase 3
show 1 more result
0.859 vs 1.295 placebo per year @ 52wk300 mg q2w
NCT04456673 · Phase 3
FEV1 0.16 vs 0.077 placebo L @ 12wk300 mg q2w
absolute change · L
NCT03930732 · Phase 3
show 31 more results
0.153 vs 0.07 placebo L @ 52wk300 mg q2w
NCT03930732 · Phase 3
0.232 vs 0.108 placebo L @ 12wk300 mg q2w
NCT03930732 · Phase 3
0.247 vs 0.12 placebo L @ 52wk300 mg q2w
NCT03930732 · Phase 3
0.159 vs 0.075 placebo L @ 2wk300 mg q2w
NCT03930732 · Phase 3
0.163 vs 0.069 placebo L @ 4wk300 mg q2w
NCT03930732 · Phase 3
0.149 vs 0.069 placebo L @ 8wk300 mg q2w
NCT03930732 · Phase 3
0.17 vs 0.068 placebo L @ 24wk300 mg q2w
NCT03930732 · Phase 3
0.155 vs 0.072 placebo L @ 36wk300 mg q2w
NCT03930732 · Phase 3
0.176 vs 0.089 placebo L @ 44wk300 mg q2w
NCT03930732 · Phase 3
0.158 vs 0.071 placebo L @ 2wk300 mg q2w
NCT03930732 · Phase 3
0.158 vs 0.08 placebo L @ 4wk300 mg q2w
NCT03930732 · Phase 3
0.153 vs 0.077 placebo L @ 8wk300 mg q2w
NCT03930732 · Phase 3
0.156 vs 0.084 placebo L @ 12wk300 mg q2w
NCT03930732 · Phase 3
0.169 vs 0.072 placebo L @ 24wk300 mg q2w
NCT03930732 · Phase 3
0.155 vs 0.072 placebo L @ 36wk300 mg q2w
NCT03930732 · Phase 3
0.138 vs 0.058 placebo L @ 52wk300 mg q2w
NCT03930732 · Phase 3
0.139 vs 0.057 placebo L @ 12wk300 mg q2w
NCT04456673 · Phase 3
0.115 vs 0.054 placebo L @ 52wk300 mg q2w
NCT04456673 · Phase 3
0.108 vs 0.072 placebo L @ 2wk300 mg q2w
NCT04456673 · Phase 3
0.132 vs 0.077 placebo L @ 4wk300 mg q2w
NCT04456673 · Phase 3
0.133 vs 0.069 placebo L @ 8wk300 mg q2w
NCT04456673 · Phase 3
0.154 vs 0.064 placebo L @ 24wk300 mg q2w
NCT04456673 · Phase 3
0.117 vs 0.068 placebo L @ 36wk300 mg q2w
NCT04456673 · Phase 3
0.154 vs 0.065 placebo L @ 44wk300 mg q2w
NCT04456673 · Phase 3
0.101 vs 0.082 placebo L @ 2wk300 mg q2w
NCT04456673 · Phase 3
0.126 vs 0.098 placebo L @ 4wk300 mg q2w
NCT04456673 · Phase 3
0.147 vs 0.083 placebo L @ 8wk300 mg q2w
NCT04456673 · Phase 3
0.136 vs 0.064 placebo L @ 12wk300 mg q2w
NCT04456673 · Phase 3
0.152 vs 0.081 placebo L @ 24wk300 mg q2w
NCT04456673 · Phase 3
0.131 vs 0.07 placebo L @ 36wk300 mg q2w
NCT04456673 · Phase 3
0.127 vs 0.059 placebo L @ 52wk300 mg q2w
NCT04456673 · Phase 3
SGRQ Total -9.732 vs -6.369 placebo score @ 52wk300 mg q2w
absolute change · score
NCT03930732 · Phase 3
show 1 more result
-9.816 vs -6.444 placebo score @ 52wk300 mg q2w
NCT04456673 · Phase 3
SGRQ 51.5% (n=468) vs 43.1% (n=471) placebo @ 52wk300 mg q2w
responder rate · % of participants
NCT03930732 · Phase 3
show 1 more result
51.4% (n=362) vs 46.5% (n=359) placebo @ 52wk300 mg q2w
NCT04456673 · Phase 3
E-RS Total -2.694 vs -1.558 placebo score @ 52wk300 mg q2w
absolute change · score
NCT03930732 · Phase 3
FEF 25-75% 0.11 vs 0.065 placebo L @ 2wk300 mg q2w
absolute change · L
NCT03930732 · Phase 3
show 22 more results
0.115 vs 0.066 placebo L @ 4wk300 mg q2w
NCT03930732 · Phase 3
0.114 vs 0.069 placebo L @ 8wk300 mg q2w
NCT03930732 · Phase 3
0.137 vs 0.076 placebo L @ 12wk300 mg q2w
NCT03930732 · Phase 3
0.142 vs 0.08 placebo L @ 24wk300 mg q2w
NCT03930732 · Phase 3
0.132 vs 0.087 placebo L @ 36wk300 mg q2w
NCT03930732 · Phase 3
0.162 vs 0.091 placebo L @ 44wk300 mg q2w
NCT03930732 · Phase 3
0.135 vs 0.088 placebo L @ 52wk300 mg q2w
NCT03930732 · Phase 3
0.135 vs 0.074 placebo L @ 2wk300 mg q2w
NCT03930732 · Phase 3
0.144 vs 0.087 placebo L @ 4wk300 mg q2w
NCT03930732 · Phase 3
0.144 vs 0.083 placebo L @ 8wk300 mg q2w
NCT03930732 · Phase 3
0.161 vs 0.089 placebo L @ 12wk300 mg q2w
NCT03930732 · Phase 3
0.169 vs 0.093 placebo L @ 24wk300 mg q2w
NCT03930732 · Phase 3
0.161 vs 0.093 placebo L @ 36wk300 mg q2w
NCT03930732 · Phase 3
0.153 vs 0.093 placebo L @ 52wk300 mg q2w
NCT03930732 · Phase 3
0.103 vs 0.057 placebo L @ 2wk300 mg q2w
NCT04456673 · Phase 3
0.114 vs 0.056 placebo L @ 4wk300 mg q2w
NCT04456673 · Phase 3
0.134 vs 0.059 placebo L @ 8wk300 mg q2w
NCT04456673 · Phase 3
0.137 vs 0.066 placebo L @ 12wk300 mg q2w
NCT04456673 · Phase 3
0.147 vs 0.051 placebo L @ 24wk300 mg q2w
NCT04456673 · Phase 3
0.128 vs 0.073 placebo L @ 36wk300 mg q2w
NCT04456673 · Phase 3
0.154 vs 0.053 placebo L @ 44wk300 mg q2w
NCT04456673 · Phase 3
0.122 vs 0.065 placebo L @ 52wk300 mg q2w
NCT04456673 · Phase 3
Time to First Moderate or Severe Exacerbation 0.01 vs 0 placebo months @ 12wk300 mg q2w
time to event · months
NCT03930732 · Phase 3 · converted to months from 0.024 weeks as posted
show 7 more results
0.01 vs 0.01 placebo months @ 24wk*300 mg q2w
NCT03930732 · Phase 3 · converted to months from 0.034 weeks as posted
0.01 vs 0.01 placebo months @ 36wk*300 mg q2w
NCT03930732 · Phase 3 · converted to months from 0.039 weeks as posted
0.01 vs 0.01 placebo months @ 52wk*300 mg q2w
NCT03930732 · Phase 3 · converted to months from 0.043 weeks as posted
0.02 vs 0.04 placebo months @ 12wk*300 mg q2w
NCT04456673 · Phase 3 · converted to months from 0.108 weeks as posted
0.05 vs 0.06 placebo months @ 24wk*300 mg q2w
NCT04456673 · Phase 3 · converted to months from 0.206 weeks as posted
0.07 vs 0.08 placebo months @ 36wk*300 mg q2w
NCT04456673 · Phase 3 · converted to months from 0.292 weeks as posted
0.08 vs 0.1 placebo months @ 52wk*300 mg q2w
NCT04456673 · Phase 3 · converted to months from 0.361 weeks as posted

Atopic Dermatitis

Shared mechanism: IL-4R-alpha · full Atopic Dermatitis pipeline

dupilumab · Dupixent

Marketed by Regeneron Pharmaceuticals and partners

Approved in Atopic Dermatitismonoclonal antibody
Weak signal

NCT01949311 · Phase 3 · completed

This was an explicitly described open-label extension enrolling participants from prior dupilumab atopic dermatitis trials, including the SOLO 1 and SOLO 2 programs, with 2,677 participants receiving dupilumab in a single group. The primary outcomes were safety events rather than a comparative efficacy endpoint, and there was no randomization, blinding, or control arm; therefore, the findings provide limited evidence despite the large enrollment. Its registered primary outcome on ClinicalTrials.gov is "Number of Treatment Emergent Adverse Events (TEAEs)" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: November 2026 · NCT06389136 (registry estimate)

Reported efficacy

Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16: Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 (At week 16): Dupilumab Q2W 40.3% vs Matching Placebo 16.7% (met)

Result source: NCT04417894

Rademikibart

Developed by Connect Biopharma and partners

Phase 3 in Atopic Dermatitismonoclonal antibody
Partial signal

NCT05017480 · Phase 2 · completed

SEASIDE CHINA was a randomized, double-blind, placebo-controlled Phase 2 trial in 330 Chinese adults and adolescents with moderate to severe atopic dermatitis, randomized 2:1 to rademikibart or placebo for 16 weeks. The primary endpoint was vIGA 0 or 1 with a reduction of at least 2 points at week 16. It was reached by 29.0% on rademikibart vs 5.9% on placebo (P<0.001), so the primary was met. Source: the SEASIDE CHINA paper (Br J Dermatol 2026).

Reported efficacy

Investigator Global Assessment (IGA) (0-1) (Baseline to Week16): vIGA 0/1 with a reduction of 2 points or more at week 16: rademikibart 300 mg Q2W 29.0% vs placebo 5.9%, P<0.001 (SEASIDE CHINA, Br J Dermatol 2026). (met)

Result source: NCT05017480

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointdupilumabRademikibart
EASI-7562.6% vs 29.6%+33 vs placebo300 mg Q2W · wk 16 · n 107NCT02755649
21 other results
  • 38.1% vs 8.2% 300 mg Q4W · wk 16 · n 84 · Phase 3 · primary NCT03054428
  • 59.1% vs 29.6% 300 mg QW · wk 16 · n 110 · Phase 3 · primary NCT02755649
  • 41.5% vs 8.2% 200 mg or 300 mg Q2W · wk 16 · n 82 · Phase 3 · primary NCT03054428
  • 53% vs 10.7% 200 mg or 300 mg Q4W · wk 16 · n 83 · Phase 2/3 · primary NCT03346434
  • 62.6% vs 72.4% 300 mg EOW · wk 16 · n 331 · Phase 3 · primary NCT03738397
  • 51.3% vs 14.7% 300 mg q2w · wk 16 · n 224 · Phase 3 · secondary NCT02277743
  • 44.2% vs 11.9% 300 mg q2w · wk 16 · n 233 · Phase 3 · secondary NCT02277769
  • 63.9% vs 23.2% 300 mg qw · wk 16 · n 319 · Phase 3 · secondary NCT02260986
  • 68.9% vs 23.2% 300 mg q2w · wk 16 · n 106 · Phase 3 · secondary NCT02260986
  • 57.3% vs 14.5% 300 mg Q2W · wk 16 · n 82 · Phase 3 · secondary NCT03912259
  • 65.2% vs 21.6% 300 mg q2w · wk 52 · n 89 · Phase 3 · secondary NCT02260986
  • 52.5% vs 14.7% 300 mg qw · wk 16 · n 223 · Phase 3 · secondary NCT02277743
  • 48.1% vs 11.9% 300 mg qw · wk 16 · n 239 · Phase 3 · secondary NCT02277769
  • 58% vs 26.4% 300 mg Q2W · wk 16 · n 69 · Phase 3 · secondary NCT02755649
  • 69.7% vs 26.8% 300 mg Q4W · wk 16 · n 122 · Phase 3 · secondary NCT03345914
  • 64.1% vs 21.6% 300 mg qw · wk 52 · n 270 · Phase 3 · secondary NCT02260986
  • 56.5% vs 26.4% 300 mg QW · wk 16 · n 69 · Phase 3 · secondary NCT02755649
  • 67.2% vs 26.8% 100 mg or 200 mg Q2W · wk 16 · n 122 · Phase 3 · secondary NCT03345914
  • 18.2% vs 44.3% 300 mg EOW · wk 2 · n 331 · Phase 3 · secondary NCT03738397
  • 53.6% vs 19.6% 300 mg qw · wk 16 · n 97 · Phase 2 · secondary NCT02210780
  • 60.6% vs 29.2% wk 12 · n 109 · Phase 4 · secondary NCT04033367
58.6% vs 22.6%+36 vs placebo300mg Q2W · wk 16 · n 219NCT05017480
IGA 0/1 with 2-point improvement—Trial running · NCT06884891—Not posted · NCT06477835
EASI-9035.7% vs 7.6%+28.1 vs placebo300 mg q2w · wk 16 · n 224NCT02277743
10 other results
  • 30% vs 7.2% 300 mg q2w · wk 16 · n 233 · Phase 3 · secondary NCT02277769
  • 40.2% vs 6% 300 mg Q2W · wk 16 · n 82 · Phase 3 · secondary NCT03912259
  • 33.2% vs 7.6% 300 mg qw · wk 16 · n 223 · Phase 3 · secondary NCT02277743
  • 30.5% vs 7.2% 300 mg qw · wk 16 · n 239 · Phase 3 · secondary NCT02277769
  • 19% vs 2.4% 300 mg Q4W · wk 16 · n 84 · Phase 3 · secondary NCT03054428
  • 41.8% vs 7.3% 300 mg Q4W · wk 16 · n 122 · Phase 3 · secondary NCT03345914
  • 23.2% vs 2.4% 200 mg or 300 mg Q2W · wk 16 · n 82 · Phase 3 · secondary NCT03054428
  • 25.3% vs 2.8% 200 mg or 300 mg Q4W · wk 16 · n 83 · Phase 2/3 · secondary NCT03346434
  • 30.3% vs 7.3% 100 mg or 200 mg Q2W · wk 16 · n 122 · Phase 3 · secondary NCT03345914
  • 40.3% vs 61.6% 300 mg EOW · wk 16 · n 331 · Phase 3 · secondary NCT03738397
33.4% vs 6.4%+27 vs placebo300mg Q2W · wk 16 · n 219NCT05017480
EASI, % change0.1% vs 21.7%−21.6 vs placebo300 mg Q2W/QW · wk 36 · n 169NCT02395133
31 other results
  • 6.8% vs 21.7% 300 mg Q8W · wk 36 · n 84 · Phase 3 · primary NCT02395133
  • 3.8% vs 21.7% 300 mg Q4W · wk 36 · n 86 · Phase 3 · primary NCT02395133
  • -73.9% vs -39.5% 300 mg q2w · wk 16 · n 173 · Phase 3 · secondary NCT02277743
  • -69.6% vs -33.7% 300 mg q2w · wk 16 · n 197 · Phase 3 · secondary NCT02277769
  • -80.5% vs -48.4% 300 mg q2w · wk 16 · n 92 · Phase 3 · secondary NCT02260986
  • -75.2% vs -39.4% 300 mg Q2W · wk 16 · n 82 · Phase 3 · secondary NCT03912259
  • -70.4% vs -35.3% 300 mg Q2W · wk 12 · n 82 · Phase 3 · secondary NCT03912259
  • -55.8% vs -19.3% 300 mg Q2W · wk 4 · n 82 · Phase 3 · secondary NCT03912259
  • -82.1% vs -48.6% 300 mg Q4W · wk 16 · n 122 · Phase 3 · secondary NCT03345914
  • -87.8% vs -60.9% 300 mg qw · wk 52 · n 270 · Phase 3 · secondary NCT02260986
  • -75.2% vs -39.4% 300 mg Q2W · wk 16 · n 82 · Phase 3 · secondary NCT03912259
  • -79.8% vs -46.6% 300 mg Q2W · wk 16 · n 103 · Phase 3 · secondary NCT02755649
  • -35.7% vs -10.6% 300 mg Q2W · wk 2 · n 82 · Phase 3 · secondary NCT03912259
  • -84.9% vs -60.9% 300 mg q2w · wk 52 · n 89 · Phase 3 · secondary NCT02260986
  • -73.8% vs -39.5% 300 mg qw · wk 16 · n 162 · Phase 3 · secondary NCT02277743
  • -71.6% vs -33.7% 300 mg qw · wk 16 · n 181 · Phase 3 · secondary NCT02277769
  • -81.5% vs -48.4% 300 mg qw · wk 16 · n 269 · Phase 3 · secondary NCT02260986
  • -65.8% vs -29.4% 300 mg Q2W · wk 8 · n 82 · Phase 3 · secondary NCT03912259
  • -64.8% vs -23.6% 300 mg Q4W · wk 16 · n 84 · Phase 3 · secondary NCT03054428
  • -78.2% vs -46.6% 300 mg QW · wk 16 · n 105 · Phase 3 · secondary NCT02755649
  • -65.9% vs -23.6% 200 mg or 300 mg Q2W · wk 16 · n 82 · Phase 3 · secondary NCT03054428
  • -70% vs -19.6% 200 mg or 300 mg Q4W · wk 16 · n 83 · Phase 2/3 · secondary NCT03346434
  • -78.4% vs -48.6% 100 mg or 200 mg Q2W · wk 16 · n 122 · Phase 3 · secondary NCT03345914
  • -70.5% vs -20.2% 300 mg q2w · wk 16 · n 63 · Phase 2 · primary NCT01859988
  • -74% vs -23.3% 300 mg · wk 12 · n 55 · Phase 2 · primary NCT01548404
  • -75.5% vs -20.2% 300 mg qw · wk 16 · n 61 · Phase 2 · primary NCT01859988
  • -64.9% vs -20.2% 300 mg q4w · wk 16 · n 65 · Phase 2 · primary NCT01859988
  • -75.2% vs -5.8% 200 mg qw · wk 16 · n 27 · Phase 2 · primary NCT01979016
  • -67.4% vs -20.2% 200 mg q2w · wk 16 · n 60 · Phase 2 · primary NCT01859988
  • -46.7% vs -20.2% 100 mg q4w · wk 16 · n 64 · Phase 2 · primary NCT01859988
  • -75.6% vs -52.5% 300 mg · wk 4 · n 21 · Phase 2 · secondary NCT01639040
-57.6% vs -39.7%−17.9 vs placebo150 Q2W · wk 16 · n 57NCT04444752
2 other results
  • -63.0% vs -39.7% 300 Q2W · wk 16 · n 57 · Phase 2 · primary NCT04444752
  • -63.5% vs -39.7% 300 Q4W · wk 16 · n 56 · Phase 2 · primary NCT04444752

EASI-75

dupilumab
62.6% vs 29.6%+33 vs placebo300 mg Q2W · wk 16 · n 107NCT02755649
21 other results
  • 38.1% vs 8.2% 300 mg Q4W · wk 16 · n 84 · Phase 3 · primary NCT03054428
  • 59.1% vs 29.6% 300 mg QW · wk 16 · n 110 · Phase 3 · primary NCT02755649
  • 41.5% vs 8.2% 200 mg or 300 mg Q2W · wk 16 · n 82 · Phase 3 · primary NCT03054428
  • 53% vs 10.7% 200 mg or 300 mg Q4W · wk 16 · n 83 · Phase 2/3 · primary NCT03346434
  • 62.6% vs 72.4% 300 mg EOW · wk 16 · n 331 · Phase 3 · primary NCT03738397
  • 51.3% vs 14.7% 300 mg q2w · wk 16 · n 224 · Phase 3 · secondary NCT02277743
  • 44.2% vs 11.9% 300 mg q2w · wk 16 · n 233 · Phase 3 · secondary NCT02277769
  • 63.9% vs 23.2% 300 mg qw · wk 16 · n 319 · Phase 3 · secondary NCT02260986
  • 68.9% vs 23.2% 300 mg q2w · wk 16 · n 106 · Phase 3 · secondary NCT02260986
  • 57.3% vs 14.5% 300 mg Q2W · wk 16 · n 82 · Phase 3 · secondary NCT03912259
  • 65.2% vs 21.6% 300 mg q2w · wk 52 · n 89 · Phase 3 · secondary NCT02260986
  • 52.5% vs 14.7% 300 mg qw · wk 16 · n 223 · Phase 3 · secondary NCT02277743
  • 48.1% vs 11.9% 300 mg qw · wk 16 · n 239 · Phase 3 · secondary NCT02277769
  • 58% vs 26.4% 300 mg Q2W · wk 16 · n 69 · Phase 3 · secondary NCT02755649
  • 69.7% vs 26.8% 300 mg Q4W · wk 16 · n 122 · Phase 3 · secondary NCT03345914
  • 64.1% vs 21.6% 300 mg qw · wk 52 · n 270 · Phase 3 · secondary NCT02260986
  • 56.5% vs 26.4% 300 mg QW · wk 16 · n 69 · Phase 3 · secondary NCT02755649
  • 67.2% vs 26.8% 100 mg or 200 mg Q2W · wk 16 · n 122 · Phase 3 · secondary NCT03345914
  • 18.2% vs 44.3% 300 mg EOW · wk 2 · n 331 · Phase 3 · secondary NCT03738397
  • 53.6% vs 19.6% 300 mg qw · wk 16 · n 97 · Phase 2 · secondary NCT02210780
  • 60.6% vs 29.2% wk 12 · n 109 · Phase 4 · secondary NCT04033367
Rademikibart
58.6% vs 22.6%+36 vs placebo300mg Q2W · wk 16 · n 219NCT05017480

IGA 0/1 with 2-point improvement

dupilumab
—Trial running · NCT06884891
Rademikibart
—Not posted · NCT06477835

EASI-90

dupilumab
35.7% vs 7.6%+28.1 vs placebo300 mg q2w · wk 16 · n 224NCT02277743
10 other results
  • 30% vs 7.2% 300 mg q2w · wk 16 · n 233 · Phase 3 · secondary NCT02277769
  • 40.2% vs 6% 300 mg Q2W · wk 16 · n 82 · Phase 3 · secondary NCT03912259
  • 33.2% vs 7.6% 300 mg qw · wk 16 · n 223 · Phase 3 · secondary NCT02277743
  • 30.5% vs 7.2% 300 mg qw · wk 16 · n 239 · Phase 3 · secondary NCT02277769
  • 19% vs 2.4% 300 mg Q4W · wk 16 · n 84 · Phase 3 · secondary NCT03054428
  • 41.8% vs 7.3% 300 mg Q4W · wk 16 · n 122 · Phase 3 · secondary NCT03345914
  • 23.2% vs 2.4% 200 mg or 300 mg Q2W · wk 16 · n 82 · Phase 3 · secondary NCT03054428
  • 25.3% vs 2.8% 200 mg or 300 mg Q4W · wk 16 · n 83 · Phase 2/3 · secondary NCT03346434
  • 30.3% vs 7.3% 100 mg or 200 mg Q2W · wk 16 · n 122 · Phase 3 · secondary NCT03345914
  • 40.3% vs 61.6% 300 mg EOW · wk 16 · n 331 · Phase 3 · secondary NCT03738397
Rademikibart
33.4% vs 6.4%+27 vs placebo300mg Q2W · wk 16 · n 219NCT05017480

EASI, % change

dupilumab
0.1% vs 21.7%−21.6 vs placebo300 mg Q2W/QW · wk 36 · n 169NCT02395133
31 other results
  • 6.8% vs 21.7% 300 mg Q8W · wk 36 · n 84 · Phase 3 · primary NCT02395133
  • 3.8% vs 21.7% 300 mg Q4W · wk 36 · n 86 · Phase 3 · primary NCT02395133
  • -73.9% vs -39.5% 300 mg q2w · wk 16 · n 173 · Phase 3 · secondary NCT02277743
  • -69.6% vs -33.7% 300 mg q2w · wk 16 · n 197 · Phase 3 · secondary NCT02277769
  • -80.5% vs -48.4% 300 mg q2w · wk 16 · n 92 · Phase 3 · secondary NCT02260986
  • -75.2% vs -39.4% 300 mg Q2W · wk 16 · n 82 · Phase 3 · secondary NCT03912259
  • -70.4% vs -35.3% 300 mg Q2W · wk 12 · n 82 · Phase 3 · secondary NCT03912259
  • -55.8% vs -19.3% 300 mg Q2W · wk 4 · n 82 · Phase 3 · secondary NCT03912259
  • -82.1% vs -48.6% 300 mg Q4W · wk 16 · n 122 · Phase 3 · secondary NCT03345914
  • -87.8% vs -60.9% 300 mg qw · wk 52 · n 270 · Phase 3 · secondary NCT02260986
  • -75.2% vs -39.4% 300 mg Q2W · wk 16 · n 82 · Phase 3 · secondary NCT03912259
  • -79.8% vs -46.6% 300 mg Q2W · wk 16 · n 103 · Phase 3 · secondary NCT02755649
  • -35.7% vs -10.6% 300 mg Q2W · wk 2 · n 82 · Phase 3 · secondary NCT03912259
  • -84.9% vs -60.9% 300 mg q2w · wk 52 · n 89 · Phase 3 · secondary NCT02260986
  • -73.8% vs -39.5% 300 mg qw · wk 16 · n 162 · Phase 3 · secondary NCT02277743
  • -71.6% vs -33.7% 300 mg qw · wk 16 · n 181 · Phase 3 · secondary NCT02277769
  • -81.5% vs -48.4% 300 mg qw · wk 16 · n 269 · Phase 3 · secondary NCT02260986
  • -65.8% vs -29.4% 300 mg Q2W · wk 8 · n 82 · Phase 3 · secondary NCT03912259
  • -64.8% vs -23.6% 300 mg Q4W · wk 16 · n 84 · Phase 3 · secondary NCT03054428
  • -78.2% vs -46.6% 300 mg QW · wk 16 · n 105 · Phase 3 · secondary NCT02755649
  • -65.9% vs -23.6% 200 mg or 300 mg Q2W · wk 16 · n 82 · Phase 3 · secondary NCT03054428
  • -70% vs -19.6% 200 mg or 300 mg Q4W · wk 16 · n 83 · Phase 2/3 · secondary NCT03346434
  • -78.4% vs -48.6% 100 mg or 200 mg Q2W · wk 16 · n 122 · Phase 3 · secondary NCT03345914
  • -70.5% vs -20.2% 300 mg q2w · wk 16 · n 63 · Phase 2 · primary NCT01859988
  • -74% vs -23.3% 300 mg · wk 12 · n 55 · Phase 2 · primary NCT01548404
  • -75.5% vs -20.2% 300 mg qw · wk 16 · n 61 · Phase 2 · primary NCT01859988
  • -64.9% vs -20.2% 300 mg q4w · wk 16 · n 65 · Phase 2 · primary NCT01859988
  • -75.2% vs -5.8% 200 mg qw · wk 16 · n 27 · Phase 2 · primary NCT01979016
  • -67.4% vs -20.2% 200 mg q2w · wk 16 · n 60 · Phase 2 · primary NCT01859988
  • -46.7% vs -20.2% 100 mg q4w · wk 16 · n 64 · Phase 2 · primary NCT01859988
  • -75.6% vs -52.5% 300 mg · wk 4 · n 21 · Phase 2 · secondary NCT01639040
Rademikibart
-57.6% vs -39.7%−17.9 vs placebo150 Q2W · wk 16 · n 57NCT04444752
2 other results
  • -63.0% vs -39.7% 300 Q2W · wk 16 · n 57 · Phase 2 · primary NCT04444752
  • -63.5% vs -39.7% 300 Q4W · wk 16 · n 56 · Phase 2 · primary NCT04444752
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. dupilumab: 6 of 6 rows · Rademikibart: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricdupilumab
Rows use multiple source trials
Rademikibart
Rows use multiple source trials
IGA 0/1
responder rate · % of participants
37.9% (n=224) vs 10.3% (n=224) placebo @ 16wk300 mg q2wa,b,c,d
NCT02277743 · Phase 3
show 1 more dose
37.2% (n=223) vs 10.3% (n=224) placebo @ 16wk300 mg qw
NCT02277743 · Phase 3
29% (n=219) vs 5.9% (n=111) placebo @ 16wk300mg Q2Wb,c,d
NCT05017480 · Phase 2
3 other source trials
15.8% (n=57) vs 8.9% (n=56) placebo @ 16wk*150 Q2W
NCT04444752 · Phase 2 · registry result, not featured evidence · converted to % from 9 Participants as posted
28.1% (n=57) vs 8.9% (n=56) placebo @ 16wk*300 Q2W
NCT04444752 · Phase 2 · registry result, not featured evidence · converted to % from 16 Participants as posted
19.6% (n=56) vs 8.9% (n=56) placebo @ 16wk*300 Q4W
NCT04444752 · Phase 2 · registry result, not featured evidence · converted to % from 11 Participants as posted
Itch NRS 3
responder rate · % of participants
38.6% (n=83) vs 9.4% (n=85) placebo @ 16wk300 mg Q4Wa,b,c,d
NCT03054428 · Phase 3
show 1 more dose
48.8% (n=82) vs 9.4% (n=85) placebo @ 16wk200 mg or 300 mg Q2W
NCT03054428 · Phase 3
50% (n=218) vs 20.3% (n=111) placebo @ 16wk300mg Q2Wb,c,d
NCT05017480 · Phase 2
Dropout rate
51.6%e
NCT01949311 · Phase 3 · monotherapy
show 51 more results
7.1%300 mg q2w
NCT02277743 · Phase 3
11.7%300 mg qw
NCT02277743 · Phase 3
5.6%300 mg q2w
NCT02277769 · Phase 3
7.5%300 mg qw
NCT02277769 · Phase 3
12.3%300 mg q2w
NCT02260986 · Phase 3
12.9%300 mg qw
NCT02260986 · Phase 3
8.3%300 mg Q2W/QW
NCT02395133 · Phase 3
11.6%300 mg Q4W
NCT02395133 · Phase 3
10.7%300 mg Q8W
NCT02395133 · Phase 3
95.2%300 mg Q4W
NCT03054428 · Phase 3
—200 mg or 300 mg
NCT03054428 · Phase 3
96.3%200 mg or 300 mg Q2W
NCT03054428 · Phase 3
n/a: no completion milestone300 mg Q4W
NCT03345914 · Phase 3 · combination
n/a: no completion milestone100 mg or 200 mg Q2W
NCT03345914 · Phase 3 · combination
98.8%200 mg or 300 mg Q4W
NCT03346434 · Phase 2/3 · combination
0%6 mg/kg
NCT03346434 · Phase 2/3
0%6 mg/kg
NCT03346434 · Phase 2/3
0%3 mg/kg
NCT03346434 · Phase 2/3
10%3 mg/kg
NCT03346434 · Phase 2/3
10.4%Q2W
NCT04417894 · Phase 3
3.2%
NCT05590585 · Phase 4 · registry result, not featured evidence
17.6%
NCT03293030 · Phase 4 · registry result, not featured evidence
29.4%
NCT03667014 · Phase 4 · registry result, not featured evidence
—Atopic Dermatitis Participant
NCT04718870 · Phase 4 · registry result, not featured evidence
0%Atopic Dermatitis Participants
NCT04718870 · Phase 4 · registry result, not featured evidence
20%
NCT04823130 · Phase 4 · registry result, not featured evidence
—DB Period: Dupilumab
NCT04033367 · Phase 4 · registry result, not featured evidence
3.9%Dupilumab/Dupilumab
NCT04033367 · Phase 4 · registry result, not featured evidence
—OLE Period: Dupilumab/Dupilumab
NCT04033367 · Phase 4 · registry result, not featured evidence
0%
NCT04447417 · Phase 4 · registry result, not featured evidence
6.9%300 mg EOW
NCT03738397 · Phase 3 · registry result, not featured evidence
7.3%300 mg Q2W
NCT03912259 · Phase 3 · registry result, not featured evidence
92.5%300 mg Q2W
NCT02755649 · Phase 3 · registry result, not featured evidence · combination
92.7%300 mg QW
NCT02755649 · Phase 3 · registry result, not featured evidence · combination
0%
NCT03359356 · Phase 2 · registry result, not featured evidence
—4 mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
—4 mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
0%4mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
0%4mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
0%2mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
0%2mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
8.2%300 mg qw
NCT02210780 · Phase 2 · registry result, not featured evidence
3.7%200 mg qw
NCT01979016 · Phase 2 · registry result, not featured evidence
18.8%300 mg q2w
NCT01859988 · Phase 2 · registry result, not featured evidence
15.4%300 mg q4w
NCT01859988 · Phase 2 · registry result, not featured evidence
17.5%300 mg qw
NCT01859988 · Phase 2 · registry result, not featured evidence
45.2%200 mg q2w
NCT01859988 · Phase 2 · registry result, not featured evidence
35.4%100 mg q4w
NCT01859988 · Phase 2 · registry result, not featured evidence
25.5%300 mg
NCT01548404 · Phase 2 · registry result, not featured evidence
—300 mg
NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy
0%300 mg QW
NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy
4.6%300mg Q2We
NCT05017480 · Phase 2
show 6 more results
—300mg Q2W
NCT05017480 · Phase 2
—300mg Q4W
NCT05017480 · Phase 2
—300mg Q2W
NCT05017480 · Phase 2
19.3%150 Q2W
NCT04444752 · Phase 2 · registry result, not featured evidence
21.1%300 Q2W
NCT04444752 · Phase 2 · registry result, not featured evidence
10.7%300 Q4W
NCT04444752 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
4%e
NCT01949311 · Phase 3 · monotherapy
show 51 more results
2.7%300 mg q2w
NCT02277743 · Phase 3
2.7%300 mg qw
NCT02277743 · Phase 3
0.9%300 mg q2w
NCT02277769 · Phase 3
1.7%300 mg qw
NCT02277769 · Phase 3
0%300 mg q2w
NCT02260986 · Phase 3
3.4%300 mg qw
NCT02260986 · Phase 3
0%300 mg Q2W/QW
NCT02395133 · Phase 3
3.5%300 mg Q4W
NCT02395133 · Phase 3
1.2%300 mg Q8W
NCT02395133 · Phase 3
—300 mg Q4W
NCT03054428 · Phase 3
—200 mg or 300 mg
NCT03054428 · Phase 3
—200 mg or 300 mg Q2W
NCT03054428 · Phase 3
—300 mg Q4W
NCT03345914 · Phase 3 · combination
—100 mg or 200 mg Q2W
NCT03345914 · Phase 3 · combination
—200 mg or 300 mg Q4W
NCT03346434 · Phase 2/3 · combination
—6 mg/kg
NCT03346434 · Phase 2/3
—6 mg/kg
NCT03346434 · Phase 2/3
—3 mg/kg
NCT03346434 · Phase 2/3
—3 mg/kg
NCT03346434 · Phase 2/3
—Q2W
NCT04417894 · Phase 3
—
NCT05590585 · Phase 4 · registry result, not featured evidence
—
NCT03293030 · Phase 4 · registry result, not featured evidence
—
NCT03667014 · Phase 4 · registry result, not featured evidence
—Atopic Dermatitis Participant
NCT04718870 · Phase 4 · registry result, not featured evidence
—Atopic Dermatitis Participants
NCT04718870 · Phase 4 · registry result, not featured evidence
—
NCT04823130 · Phase 4 · registry result, not featured evidence
—DB Period: Dupilumab
NCT04033367 · Phase 4 · registry result, not featured evidence
0.8%Dupilumab/Dupilumab
NCT04033367 · Phase 4 · registry result, not featured evidence
—OLE Period: Dupilumab/Dupilumab
NCT04033367 · Phase 4 · registry result, not featured evidence
—
NCT04447417 · Phase 4 · registry result, not featured evidence
0.9%300 mg EOW
NCT03738397 · Phase 3 · registry result, not featured evidence
4.9%300 mg Q2W
NCT03912259 · Phase 3 · registry result, not featured evidence
—300 mg Q2W
NCT02755649 · Phase 3 · registry result, not featured evidence · combination
—300 mg QW
NCT02755649 · Phase 3 · registry result, not featured evidence · combination
—
NCT03359356 · Phase 2 · registry result, not featured evidence
—4 mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
—4 mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
—4mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
—4mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
—2mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
—2mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
5.2%300 mg qw
NCT02210780 · Phase 2 · registry result, not featured evidence
3.7%200 mg qw
NCT01979016 · Phase 2 · registry result, not featured evidence
1.6%300 mg q2w
NCT01859988 · Phase 2 · registry result, not featured evidence
1.5%300 mg q4w
NCT01859988 · Phase 2 · registry result, not featured evidence
3.2%300 mg qw
NCT01859988 · Phase 2 · registry result, not featured evidence
4.8%200 mg q2w
NCT01859988 · Phase 2 · registry result, not featured evidence
3.1%100 mg q4w
NCT01859988 · Phase 2 · registry result, not featured evidence
1.8%300 mg
NCT01548404 · Phase 2 · registry result, not featured evidence
—300 mg
NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy
0%300 mg QW
NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy
0.5%300mg Q2We
NCT05017480 · Phase 2
show 6 more results
—300mg Q2W
NCT05017480 · Phase 2
—300mg Q4W
NCT05017480 · Phase 2
—300mg Q2W
NCT05017480 · Phase 2
1.8%150 Q2W
NCT04444752 · Phase 2 · registry result, not featured evidence
0%300 Q2W
NCT04444752 · Phase 2 · registry result, not featured evidence
0%300 Q4W
NCT04444752 · Phase 2 · registry result, not featured evidence
Serious AEs
10.6%e
NCT01949311 · Phase 3 · monotherapy
show 51 more results
3.1%300 mg q2w
NCT02277743 · Phase 3
0.9%300 mg qw
NCT02277743 · Phase 3
2.5%300 mg q2w
NCT02277769 · Phase 3
3.8%300 mg qw
NCT02277769 · Phase 3
3.6%300 mg q2w
NCT02260986 · Phase 3
3.8%300 mg qw
NCT02260986 · Phase 3
3.6%300 mg Q2W/QW
NCT02395133 · Phase 3
4.6%300 mg Q4W
NCT02395133 · Phase 3
3.6%300 mg Q8W
NCT02395133 · Phase 3
0%300 mg Q4W
NCT03054428 · Phase 3
0%200 mg or 300 mg
NCT03054428 · Phase 3
—200 mg or 300 mg Q2W
NCT03054428 · Phase 3
2.5%300 mg Q4W
NCT03345914 · Phase 3 · combination
0%100 mg or 200 mg Q2W
NCT03345914 · Phase 3 · combination
0%200 mg or 300 mg Q4W
NCT03346434 · Phase 2/3 · combination
0%6 mg/kg
NCT03346434 · Phase 2/3
0%6 mg/kg
NCT03346434 · Phase 2/3
10%3 mg/kg
NCT03346434 · Phase 2/3
10%3 mg/kg
NCT03346434 · Phase 2/3
4.5%Q2W
NCT04417894 · Phase 3
5.6%
NCT05590585 · Phase 4 · registry result, not featured evidence
0%
NCT03293030 · Phase 4 · registry result, not featured evidence
0%
NCT03667014 · Phase 4 · registry result, not featured evidence
0%Atopic Dermatitis Participant
NCT04718870 · Phase 4 · registry result, not featured evidence
—Atopic Dermatitis Participants
NCT04718870 · Phase 4 · registry result, not featured evidence
3.2%
NCT04823130 · Phase 4 · registry result, not featured evidence
1.6%DB Period: Dupilumab
NCT04033367 · Phase 4 · registry result, not featured evidence
—Dupilumab/Dupilumab
NCT04033367 · Phase 4 · registry result, not featured evidence
0.8%OLE Period: Dupilumab/Dupilumab
NCT04033367 · Phase 4 · registry result, not featured evidence
0%
NCT04447417 · Phase 4 · registry result, not featured evidence
2.1%300 mg EOW
NCT03738397 · Phase 3 · registry result, not featured evidence
1.2%300 mg Q2W
NCT03912259 · Phase 3 · registry result, not featured evidence
1.9%300 mg Q2W
NCT02755649 · Phase 3 · registry result, not featured evidence · combination
2.7%300 mg QW
NCT02755649 · Phase 3 · registry result, not featured evidence · combination
2.5%
NCT03359356 · Phase 2 · registry result, not featured evidence
5%4 mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
10.5%4 mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
—4mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
—4mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
5%2mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
0%2mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
3.1%300 mg qw
NCT02210780 · Phase 2 · registry result, not featured evidence
0%200 mg qw
NCT01979016 · Phase 2 · registry result, not featured evidence
3.1%300 mg q2w
NCT01859988 · Phase 2 · registry result, not featured evidence
4.6%300 mg q4w
NCT01859988 · Phase 2 · registry result, not featured evidence
1.6%300 mg qw
NCT01859988 · Phase 2 · registry result, not featured evidence
1.6%200 mg q2w
NCT01859988 · Phase 2 · registry result, not featured evidence
7.7%100 mg q4w
NCT01859988 · Phase 2 · registry result, not featured evidence
1.8%300 mg
NCT01548404 · Phase 2 · registry result, not featured evidence
0%300 mg
NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy
—300 mg QW
NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy
0.5%300mg Q2We
NCT05017480 · Phase 2
show 6 more results
0.9%300mg Q2W
NCT05017480 · Phase 2
2.7%300mg Q4W
NCT05017480 · Phase 2
7.1%300mg Q2W
NCT05017480 · Phase 2
1.8%150 Q2W
NCT04444752 · Phase 2 · registry result, not featured evidence
0%300 Q2W
NCT04444752 · Phase 2 · registry result, not featured evidence
3.6%300 Q4W
NCT04444752 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
e
nasopharyngitis 28.9%
dermatitis atopic 16.7%
upper respiratory tract infection 13.6%
NCT01949311 · Phase 3 · monotherapy
show 44 more results
300 mg q2w
dermatitis atopic 15.3% (placebo 29.7%)
nasopharyngitis 11.8% (placebo 9.9%)
headache 9.2% (placebo 5.9%)
NCT02277743 · Phase 3
300 mg qw
injection site reaction 18.8% (placebo 5.9%)
nasopharyngitis 11.9% (placebo 9.9%)
dermatitis atopic 9.6% (placebo 29.7%)
NCT02277743 · Phase 3
300 mg q2w
dermatitis atopic 14.4% (placebo 35%)
injection site reaction 13.6% (placebo 6.4%)
nasopharyngitis 9.7% (placebo 10.7%)
NCT02277769 · Phase 3
300 mg qw
dermatitis atopic 16.5% (placebo 35%)
injection site reaction 13.1% (placebo 6.4%)
headache 9.7% (placebo 5.1%)
NCT02277769 · Phase 3
300 mg q2w
dermatitis atopic 36.4% (placebo 51.1%)
nasopharyngitis 23.6% (placebo 19.7%)
injection site reaction 14.5% (placebo 7.6%)
NCT02260986 · Phase 3
300 mg qw
dermatitis atopic 28.9% (placebo 51.1%)
nasopharyngitis 20% (placebo 19.7%)
injection site reaction 19% (placebo 7.6%)
NCT02260986 · Phase 3
300 mg Q2W/QW
dermatitis atopic 20.4% (placebo 48.8%)
nasopharyngitis 19.2% (placebo 13.4%)
upper respiratory tract infection 7.8% (placebo 7.3%)
NCT02395133 · Phase 3
300 mg Q4W
dermatitis atopic 34.5% (placebo 48.8%)
nasopharyngitis 12.6% (placebo 13.4%)
bronchitis 5.7% (placebo 1.2%)
NCT02395133 · Phase 3
300 mg Q8W
dermatitis atopic 32.1% (placebo 48.8%)
nasopharyngitis 13.1% (placebo 13.4%)
upper respiratory tract infection 8.3% (placebo 7.3%)
NCT02395133 · Phase 3
300 mg Q4W
dermatitis atopic 19.3% (placebo 24.7%)
nasopharyngitis 12% (placebo 4.7%)
upper respiratory tract infection 8.4% (placebo 17.6%)
NCT03054428 · Phase 3
200 mg or 300 mg
dermatitis atopic 18.3% (placebo 24.7%)
upper respiratory tract infection 12.2% (placebo 17.6%)
headache 11% (placebo 10.6%)
NCT03054428 · Phase 3
300 mg Q4W
nasopharyngitis 12.5% (placebo 6.7%)
upper respiratory tract infection 11.7% (placebo 10%)
dermatitis atopic 6.7% (placebo 14.2%)
NCT03345914 · Phase 3 · combination
100 mg or 200 mg Q2W
upper respiratory tract infection 9.8% (placebo 10%)
dermatitis atopic 8.2% (placebo 14.2%)
nasopharyngitis 6.6% (placebo 6.7%)
NCT03345914 · Phase 3 · combination
200 mg or 300 mg Q4W
dermatitis atopic 14.5% (placebo 30.8%)
nasopharyngitis 8.4% (placebo 9%)
upper respiratory tract infection 6% (placebo 9%)
NCT03346434 · Phase 2/3 · combination
6 mg/kg
nasopharyngitis 20% (placebo 9%)
cough 10% (placebo 6.4%)
dermatitis atopic 10% (placebo 30.8%)
NCT03346434 · Phase 2/3
6 mg/kg
cough 10% (placebo 6.4%)
nasopharyngitis 10% (placebo 9%)
skin abrasion 10% (placebo 0%)
NCT03346434 · Phase 2/3
3 mg/kg
pyrexia 20% (placebo 9%)
constipation 10% (placebo 0%)
cough 10% (placebo 6.4%)
NCT03346434 · Phase 2/3
3 mg/kg
dermatitis atopic 10% (placebo 30.8%)
impetigo 10% (placebo 7.7%)
nasopharyngitis 10% (placebo 9%)
NCT03346434 · Phase 2/3
Q2W
nasopharyngitis 23.9% (placebo 12.1%)
covid-19 16.4% (placebo 21.2%)
upper respiratory tract infection 10.4% (placebo 4.5%)
NCT04417894 · Phase 3
eye irritation 35.3%
oral/facial herpes simplex 17.6%
covid19 (moderate) 5.9%
NCT03293030 · Phase 4 · registry result, not featured evidence
eye redness 2.9%
eyelid swelling 2.9%
facial erythema 2.9%
NCT03667014 · Phase 4 · registry result, not featured evidence
dermatitis atopic 39.1%
medical device site haemorrhage 26.1%
upper respiratory tract infection 17.4%
NCT04718870 · Phase 4 · registry result, not featured evidence
headache 22.6%
dermatitis atopic 9.7%
conjunctivitis 6.5%
NCT04823130 · Phase 4 · registry result, not featured evidence
conjunctivitis 9.4% (placebo 4.9%)
headache 7.1% (placebo 8.2%)
dermatitis atopic 3.1% (placebo 13.1%)
NCT04033367 · Phase 4 · registry result, not featured evidence
accidental overdose 12.3% (placebo 0%)
conjunctivitis 2.5% (placebo 4.9%)
dermatitis atopic 2.5% (placebo 13.1%)
NCT04033367 · Phase 4 · registry result, not featured evidence
injection site reaction 19.2%
arthralgia 11.5%
food allergy 7.7%
NCT04447417 · Phase 4 · registry result, not featured evidence
300 mg EOW
conjunctivitis 10.6%
dermatitis atopic 9.7%
nasopharyngitis 8.2%
NCT03738397 · Phase 3 · registry result, not featured evidence
300 mg Q2W
dermatitis atopic 43.9% (placebo 49.4%)
upper respiratory tract infection 17.1% (placebo 12%)
protein urine present 11% (placebo 10.8%)
NCT03912259 · Phase 3 · registry result, not featured evidence
300 mg Q2W
nasopharyngitis 20.6% (placebo 16.7%)
conjunctivitis allergic 15% (placebo 6.5%)
conjunctivitis 11.2% (placebo 3.7%)
NCT02755649 · Phase 3 · registry result, not featured evidence · combination
300 mg QW
nasopharyngitis 16.4% (placebo 16.7%)
headache 10% (placebo 9.3%)
conjunctivitis allergic 9.1% (placebo 6.5%)
NCT02755649 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 15% (placebo 10%)
other orthopedic injuries/procedures 12.5% (placebo 5%)
conjuctivitis 10% (placebo 0%)
NCT03359356 · Phase 2 · registry result, not featured evidence
4 mg/kg
nasopharyngitis 40%
dermatitis atopic 15%
abdominal pain upper 10%
NCT02407756 · Phase 2 · registry result, not featured evidence
4 mg/kg
nasopharyngitis 52.6%
cough 36.8%
dermatitis atopic 26.3%
NCT02407756 · Phase 2 · registry result, not featured evidence
2mg/kg
dermatitis atopic 10%
influenza 10%
nasopharyngitis 10%
NCT02407756 · Phase 2 · registry result, not featured evidence
2mg/kg
dermatitis atopic 27.8%
nasopharyngitis 27.8%
cheilitis 5.6%
NCT02407756 · Phase 2 · registry result, not featured evidence
300 mg qw
upper respiratory tract infection 11.3% (placebo 14.4%)
conjunctivitis 8.2% (placebo 0%)
headache 5.2% (placebo 3.1%)
NCT02210780 · Phase 2 · registry result, not featured evidence
200 mg qw
dermatitis atopic 14.8% (placebo 14.8%)
upper respiratory tract infection 14.8% (placebo 14.8%)
nasopharyngitis 11.1% (placebo 18.5%)
NCT01979016 · Phase 2 · registry result, not featured evidence
300 mg q2w
nasopharyngitis 25% (placebo 26.2%)
dermatitis atopic 20.3% (placebo 16.4%)
upper respiratory tract infection 9.4% (placebo 18%)
NCT01859988 · Phase 2 · registry result, not featured evidence
300 mg q4w
nasopharyngitis 32.3% (placebo 26.2%)
dermatitis atopic 15.4% (placebo 16.4%)
headache 7.7% (placebo 3.3%)
NCT01859988 · Phase 2 · registry result, not featured evidence
300 mg qw
nasopharyngitis 25.4% (placebo 26.2%)
dermatitis atopic 12.7% (placebo 16.4%)
headache 12.7% (placebo 3.3%)
NCT01859988 · Phase 2 · registry result, not featured evidence
200 mg q2w
nasopharyngitis 26.2% (placebo 26.2%)
headache 14.8% (placebo 3.3%)
dermatitis atopic 13.1% (placebo 16.4%)
NCT01859988 · Phase 2 · registry result, not featured evidence
100 mg q4w
nasopharyngitis 30.8% (placebo 26.2%)
dermatitis atopic 16.9% (placebo 16.4%)
headache 10.8% (placebo 3.3%)
NCT01859988 · Phase 2 · registry result, not featured evidence
300 mg
nasopharyngitis 40% (placebo 18.5%)
headache 16.4% (placebo 13%)
conjunctivitis 14.5% (placebo 3.7%)
NCT01548404 · Phase 2 · registry result, not featured evidence
300 mg
nasopharyngitis 23.8% (placebo 20%)
headache 14.3% (placebo 10%)
oropharyngeal pain 14.3% (placebo 10%)
NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy
300mg Q2We
atopic dermatitis 10.5% (placebo 17.1%)
hyperlipidaemia 10.5% (placebo 5.4%)
hyperuricemia 9.6% (placebo 4.5%)
NCT05017480 · Phase 2
show 6 more results
300mg Q2W
covid-19 33.6% (placebo 0%)
atopic dermatitis 12.4% (placebo 17.1%)
upper respiratory infection 10.6% (placebo 6.3%)
NCT05017480 · Phase 2
300mg Q4W
covid-19 30.4% (placebo 0%)
atopic dermatitis 24.1% (placebo 17.1%)
upper respiratory infection 10.7% (placebo 6.3%)
NCT05017480 · Phase 2
300mg Q2W
covid-19 24.7% (placebo 0%)
upper respiratory infection 17.6% (placebo 6.3%)
atopic dermatitis 16.5% (placebo 17.1%)
NCT05017480 · Phase 2
150 Q2W
dermatitis atopic 12.3% (placebo 14.3%)
covid-19 7% (placebo 7.1%)
urinary tract infection 7% (placebo 1.8%)
NCT04444752 · Phase 2 · registry result, not featured evidence
300 Q2W
dermatitis atopic 8.8% (placebo 14.3%)
nasopharyngitis 5.3% (placebo 7.1%)
conjunctivitis 3.5% (placebo 0%)
NCT04444752 · Phase 2 · registry result, not featured evidence
300 Q4W
dermatitis atopic 25% (placebo 14.3%)
headache 7.1% (placebo 0%)
nausea 5.4% (placebo 0%)
NCT04444752 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2 versus Phase 3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

dupilumab

IGA 0/1 0% (n=10) @ 4wk6 mg/kg
responder rate · % of participants
No placebo or comparator arm
NCT03346434 · Phase 2/3
show 26 more results
10% (n=10) @ 4wk6 mg/kg
NCT03346434 · Phase 2/3
10% (n=10) @ 4wk3 mg/kg
NCT03346434 · Phase 2/3
10% (n=10) @ 4wk3 mg/kg
NCT03346434 · Phase 2/3
35% (n=20) @ 12wk4mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
21.1% (n=19) @ 12wk4mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
10% (n=20) @ 12wk2mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
16.7% (n=18) @ 12wk2mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
31.1% (n=2677) @ 4wk
NCT01949311 · Phase 3 · monotherapy
46.7% (n=2677) @ 16wk
NCT01949311 · Phase 3 · monotherapy
46.2% (n=2677) @ 36wk
NCT01949311 · Phase 3 · monotherapy
53.8% (n=2677) @ 52wk
NCT01949311 · Phase 3 · monotherapy
58.2% (n=2677) @ 100wk
NCT01949311 · Phase 3 · monotherapy
59.6% (n=2677) @ 124wk
NCT01949311 · Phase 3 · monotherapy
67.2% (n=2677) @ 156wk
NCT01949311 · Phase 3 · monotherapy
71.1% (n=2677) @ 172wk
NCT01949311 · Phase 3 · monotherapy
56.5% (n=2677) @ 188wk
NCT01949311 · Phase 3 · monotherapy
64.4% (n=2677) @ 204wk
NCT01949311 · Phase 3 · monotherapy
81.2% (n=2677) @ 220wk
NCT01949311 · Phase 3 · monotherapy
50% (n=2677) @ 236wk
NCT01949311 · Phase 3 · monotherapy
0.9% (n=120) @ 2wk
NCT05590585 · Phase 4 · registry result, not featured evidence
6.8% (n=120) @ 4wk
NCT05590585 · Phase 4 · registry result, not featured evidence
15.9% (n=120) @ 8wk
NCT05590585 · Phase 4 · registry result, not featured evidence
25.9% (n=120) @ 12wk
NCT05590585 · Phase 4 · registry result, not featured evidence
35.2% (n=120) @ 16wk
NCT05590585 · Phase 4 · registry result, not featured evidence
45.4% (n=120) @ 20wk
NCT05590585 · Phase 4 · registry result, not featured evidence
44% (n=120) @ 24wk
NCT05590585 · Phase 4 · registry result, not featured evidence
IGA 0/1 67.5% (n=2677) @ 272wk
responder rate · % of participants
No placebo or comparator arm
End of Study (Extension)
NCT01949311 · Phase 3 · monotherapy
EASI-75 65.3% (n=2677) @ 4wk
responder rate · % of participants
No placebo or comparator arm
NCT01949311 · Phase 3 · monotherapy
show 19 more results
82% (n=2677) @ 16wk
NCT01949311 · Phase 3 · monotherapy
85.3% (n=2677) @ 36wk
NCT01949311 · Phase 3 · monotherapy
88.8% (n=2677) @ 52wk
NCT01949311 · Phase 3 · monotherapy
91.4% (n=2677) @ 100wk
NCT01949311 · Phase 3 · monotherapy
92% (n=2677) @ 124wk
NCT01949311 · Phase 3 · monotherapy
89.5% (n=2677) @ 156wk
NCT01949311 · Phase 3 · monotherapy
94.1% (n=2677) @ 172wk
NCT01949311 · Phase 3 · monotherapy
96.8% (n=2677) @ 188wk
NCT01949311 · Phase 3 · monotherapy
90.9% (n=2677) @ 204wk
NCT01949311 · Phase 3 · monotherapy
93.5% (n=2677) @ 220wk
NCT01949311 · Phase 3 · monotherapy
100% (n=2677) @ 236wk
NCT01949311 · Phase 3 · monotherapy
3.4% (n=120) @ 2wk
NCT05590585 · Phase 4 · registry result, not featured evidence
23.1% (n=120) @ 4wk
NCT05590585 · Phase 4 · registry result, not featured evidence
50.4% (n=120) @ 8wk
NCT05590585 · Phase 4 · registry result, not featured evidence
56.5% (n=120) @ 12wk
NCT05590585 · Phase 4 · registry result, not featured evidence
63.9% (n=120) @ 16wk
NCT05590585 · Phase 4 · registry result, not featured evidence
74.2% (n=120) @ 20wk
NCT05590585 · Phase 4 · registry result, not featured evidence
76% (n=120) @ 24wk
NCT05590585 · Phase 4 · registry result, not featured evidence
76% (n=100) @ 24wk
NCT05590585 · Phase 4 · registry result, not featured evidence
EASI-75 88.9% (n=2677) @ 272wk
responder rate · % of participants
No placebo or comparator arm
End of Study (Extension)
NCT01949311 · Phase 3 · monotherapy
IGA Leq2 70% (n=2677) @ 4wk
responder rate · % of participants
No placebo or comparator arm
NCT01949311 · Phase 3 · monotherapy
show 11 more results
83% (n=2677) @ 16wk
NCT01949311 · Phase 3 · monotherapy
84.6% (n=2677) @ 36wk
NCT01949311 · Phase 3 · monotherapy
89.6% (n=2677) @ 52wk
NCT01949311 · Phase 3 · monotherapy
90.9% (n=2677) @ 100wk
NCT01949311 · Phase 3 · monotherapy
93.1% (n=2677) @ 124wk
NCT01949311 · Phase 3 · monotherapy
94.8% (n=2677) @ 156wk
NCT01949311 · Phase 3 · monotherapy
96.3% (n=2677) @ 172wk
NCT01949311 · Phase 3 · monotherapy
96.8% (n=2677) @ 188wk
NCT01949311 · Phase 3 · monotherapy
96% (n=2677) @ 204wk
NCT01949311 · Phase 3 · monotherapy
97.1% (n=2677) @ 220wk
NCT01949311 · Phase 3 · monotherapy
90% (n=2677) @ 236wk
NCT01949311 · Phase 3 · monotherapy
IGA Leq2 92.6% (n=2677) @ 272wk
responder rate · % of participants
No placebo or comparator arm
End of Study (Extension)
NCT01949311 · Phase 3 · monotherapy
EASI -8.59 score @ 4wk
absolute change · score
No placebo or comparator arm
NCT01949311 · Phase 3 · monotherapy
show 22 more results
-11.89 score @ 16wk
NCT01949311 · Phase 3 · monotherapy
-17.32 score @ 36wk
NCT01949311 · Phase 3 · monotherapy
-16.46 score @ 52wk
NCT01949311 · Phase 3 · monotherapy
-17.99 score @ 100wk
NCT01949311 · Phase 3 · monotherapy
-17.68 score @ 124wk
NCT01949311 · Phase 3 · monotherapy
-14.23 score @ 156wk
NCT01949311 · Phase 3 · monotherapy
-13.23 score @ 172wk
NCT01949311 · Phase 3 · monotherapy
-19.24 score @ 188wk
NCT01949311 · Phase 3 · monotherapy
-14.5 score @ 204wk
NCT01949311 · Phase 3 · monotherapy
-12.75 score @ 220wk
NCT01949311 · Phase 3 · monotherapy
-16.69 score @ 236wk
NCT01949311 · Phase 3 · monotherapy
-7.105 score @ 2wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-12.097 score @ 4wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-17.779 score @ 8wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-18.475 score @ 12wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-19.46 score @ 16wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-20.985 score @ 20wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-20.98 score @ 24wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-18.9 score @ 17wk
NCT04823130 · Phase 4 · registry result, not featured evidence
-19.5 score @ 21wk
NCT04823130 · Phase 4 · registry result, not featured evidence
10.6 score @ 24wk
NCT03359356 · Phase 2 · registry result, not featured evidence
10.53 score @ 48wk
NCT03359356 · Phase 2 · registry result, not featured evidence
EASI -13.14 score @ 272wk
absolute change · score
No placebo or comparator arm
End of Study (Extension)
NCT01949311 · Phase 3 · monotherapy
EASI -48.7% (n=10) @ 4wk6 mg/kg
percent change · % of baseline
No placebo or comparator arm
NCT03346434 · Phase 2/3
show 26 more results
-43.2% (n=10) @ 4wk6 mg/kg
NCT03346434 · Phase 2/3
-26.6% (n=10) @ 4wk3 mg/kg
NCT03346434 · Phase 2/3
-22.4% (n=10) @ 4wk3 mg/kg
NCT03346434 · Phase 2/3
-69.7% (n=20) @ 12wk4mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
-63.4% (n=19) @ 12wk4mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
-66.4% (n=20) @ 12wk2mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
-76.2% (n=18) @ 12wk2mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
-42.02% (n=2677) @ 4wk
NCT01949311 · Phase 3 · monotherapy
-54.82% (n=2677) @ 16wk
NCT01949311 · Phase 3 · monotherapy
-60.4% (n=2677) @ 36wk
NCT01949311 · Phase 3 · monotherapy
-75.76% (n=2677) @ 52wk
NCT01949311 · Phase 3 · monotherapy
-82.61% (n=2677) @ 100wk
NCT01949311 · Phase 3 · monotherapy
-84.15% (n=2677) @ 124wk
NCT01949311 · Phase 3 · monotherapy
-83.45% (n=2677) @ 156wk
NCT01949311 · Phase 3 · monotherapy
-74.98% (n=2677) @ 172wk
NCT01949311 · Phase 3 · monotherapy
-88.72% (n=2677) @ 188wk
NCT01949311 · Phase 3 · monotherapy
-70.91% (n=2677) @ 204wk
NCT01949311 · Phase 3 · monotherapy
-30.79% (n=2677) @ 220wk
NCT01949311 · Phase 3 · monotherapy
-87.56% (n=2677) @ 236wk
NCT01949311 · Phase 3 · monotherapy
-25.929% (n=120) @ 2wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-46.092% (n=120) @ 4wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-67.27% (n=120) @ 8wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-70.999% (n=120) @ 12wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-73.276% (n=120) @ 16wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-79.185% (n=120) @ 20wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-79.941% (n=120) @ 24wk
NCT05590585 · Phase 4 · registry result, not featured evidence
EASI -55.44% (n=2677) @ 272wk
percent change · % of baseline
No placebo or comparator arm
End of Study (Extension)
NCT01949311 · Phase 3 · monotherapy
EASI-50 86% (n=2677) @ 4wk
responder rate · % of participants
No placebo or comparator arm
NCT01949311 · Phase 3 · monotherapy
show 18 more results
95% (n=2677) @ 16wk
NCT01949311 · Phase 3 · monotherapy
96.7% (n=2677) @ 36wk
NCT01949311 · Phase 3 · monotherapy
97.4% (n=2677) @ 52wk
NCT01949311 · Phase 3 · monotherapy
98.5% (n=2677) @ 100wk
NCT01949311 · Phase 3 · monotherapy
98.3% (n=2677) @ 124wk
NCT01949311 · Phase 3 · monotherapy
97.4% (n=2677) @ 156wk
NCT01949311 · Phase 3 · monotherapy
98.4% (n=2677) @ 172wk
NCT01949311 · Phase 3 · monotherapy
100% (n=2677) @ 188wk
NCT01949311 · Phase 3 · monotherapy
94.9% (n=2677) @ 204wk
NCT01949311 · Phase 3 · monotherapy
97.8% (n=2677) @ 220wk
NCT01949311 · Phase 3 · monotherapy
100% (n=2677) @ 236wk
NCT01949311 · Phase 3 · monotherapy
17.2% (n=120) @ 2wk
NCT05590585 · Phase 4 · registry result, not featured evidence
47.9% (n=120) @ 4wk
NCT05590585 · Phase 4 · registry result, not featured evidence
77.9% (n=120) @ 8wk
NCT05590585 · Phase 4 · registry result, not featured evidence
84.3% (n=120) @ 12wk
NCT05590585 · Phase 4 · registry result, not featured evidence
84.3% (n=120) @ 16wk
NCT05590585 · Phase 4 · registry result, not featured evidence
89.7% (n=120) @ 20wk
NCT05590585 · Phase 4 · registry result, not featured evidence
89% (n=120) @ 24wk
NCT05590585 · Phase 4 · registry result, not featured evidence
EASI-50 96.9% (n=2677) @ 272wk
responder rate · % of participants
No placebo or comparator arm
End of Study (Extension)
NCT01949311 · Phase 3 · monotherapy

+ 122 further endpoints in the CSV export.

Rademikibart

PP-NRS4 36.3% (n=216) vs 10.5% (n=110) placebo @ 16wk300mg Q2W
responder rate · % of participants
NCT05017480 · Phase 2
PP-NRS -2.95 vs -0.99 placebo score @ 16wk300mg Q2W
absolute change · score
NCT05017480 · Phase 2
PP-NRS -40% (n=219) vs -13.5% (n=111) placebo @ 16wk300mg Q2W
percent change · % of baseline
NCT05017480 · Phase 2

Asthma

Shared mechanism: IL-4R-alpha · full Asthma pipeline

dupilumab · Dupixent

Marketed by Regeneron Pharmaceuticals and partners

Approved in Asthmamonoclonal antibody
Partial signal

NCT03782532 · Phase 3 · completed

The study was randomized, triple-blind, and placebo-controlled with 486 participants, which is a substantial and generally rigorous design. The primary endpoint was a lung-function measure rather than a hard clinical outcome. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source.

Next expected readout: December 2026 · NCT05347771 (registry estimate)

Reported efficacy

Change in pre-bronchodilator forced expiratory volume (FEV1) (Baseline to Week 12): Change in pre-bronchodilator FEV1, baseline to Week 12: LS mean difference 0.31 L favoring dupilumab vs placebo (95% CI 0.23-0.39); p<0.0001 (primary analysis population, n=414). (met)

Result source: NCT03782532

Rademikibart

Developed by Connect Biopharma and partners

Phase 3 in Asthmamonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT07705737 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointdupilumabRademikibart
Severe exacerbations, annualised rate0.5 vs 1.0−0.4 vs placebo300 mg q2w · wk 52 · n 633NCT02414854
7 other results
  • 0.5 vs 1.0 200 mg q2w · wk 52 · n 631 · Phase 3 · primary NCT02414854
  • 0.6 vs 1.6 300 mg q2w · wk 24 · n 103 · Phase 3 · secondary NCT02528214
  • 0.5 vs 0.1 wk 52 · n 13 · Phase 3 · secondary NCT03560466
  • 0.3 vs 0.9 300 mg q2w · wk 24 · n 156 · Phase 2 · secondary NCT01854047
  • 0.3 vs 0.9 200 mg q2w · wk 24 · n 148 · Phase 2 · secondary NCT01854047
  • 0.6 vs 0.9 300 mg q4w · wk 24 · n 157 · Phase 2 · secondary NCT01854047
  • 0.4 vs 0.9 200 mg q4w · wk 24 · n 150 · Phase 2 · secondary NCT01854047
—Trial running · NCT06488755
Trough FEV1, change0.3 vs 0.7−0.4 vs placebowk 64 · n 13NCT03560466
5 other results
  • 0.3 vs 0.6 wk 52 · n 13 · Phase 3 · secondary NCT03560466
  • 0.1 vs 0.5 wk 24 · n 13 · Phase 3 · secondary NCT03560466
  • 0.2 vs 0.4 wk 12 · n 13 · Phase 3 · secondary NCT03560466
  • 0.1 vs 0.4 wk 8 · n 13 · Phase 3 · secondary NCT03560466
  • 0.1 vs 0.4 wk 2 · n 13 · Phase 3 · secondary NCT03560466
—Trial running · NCT06488755
ACQ-5, change-1.5 vs -1.3−0.2 vs placebo300 mg q2w · wk 52 · n 633NCT02414854
19 other results
  • -1.5 vs -1.2 300 mg q2w · wk 36 · n 633 · Phase 3 · secondary NCT02414854
  • -1.4 vs -1.1 300 mg q2w · wk 12 · n 633 · Phase 3 · secondary NCT02414854
  • -1.2 vs -1.1 300 mg q2w · wk 8 · n 633 · Phase 3 · secondary NCT02414854
  • -1.1 vs -0.8 300 mg q2w · wk 4 · n 633 · Phase 3 · secondary NCT02414854
  • -0.9 vs -0.6 300 mg q2w · wk 2 · n 633 · Phase 3 · secondary NCT02414854
  • -1.5 vs -1.3 200 mg q2w · wk 52 · n 631 · Phase 3 · secondary NCT02414854
  • -1.5 vs -1.2 200 mg q2w · wk 36 · n 631 · Phase 3 · secondary NCT02414854
  • -1.3 vs -1.1 200 mg q2w · wk 12 · n 631 · Phase 3 · secondary NCT02414854
  • -1.3 vs -1.1 200 mg q2w · wk 8 · n 631 · Phase 3 · secondary NCT02414854
  • -1.1 vs -0.8 200 mg q2w · wk 4 · n 631 · Phase 3 · secondary NCT02414854
  • -0.9 vs -0.6 200 mg q2w · wk 2 · n 631 · Phase 3 · secondary NCT02414854
  • -0.9 vs -0.6 300 mg q2w · wk 24 · n 103 · Phase 3 · secondary NCT02528214
  • -0.8 vs -0.5 300 mg q2w · wk 20 · n 103 · Phase 3 · secondary NCT02528214
  • -0.9 vs -0.6 300 mg q2w · wk 16 · n 103 · Phase 3 · secondary NCT02528214
  • -0.9 vs -0.5 300 mg q2w · wk 12 · n 103 · Phase 3 · secondary NCT02528214
  • -0.7 vs -0.4 300 mg q2w · wk 8 · n 103 · Phase 3 · secondary NCT02528214
  • -0.6 vs -0.4 300 mg q2w · wk 4 · n 103 · Phase 3 · secondary NCT02528214
  • -0.5 vs -0.2 300 mg q2w · wk 2 · n 103 · Phase 3 · secondary NCT02528214
  • -1.1 vs -0.5 300 mg qw · wk 12 · n 44 · Phase 2 · secondary NCT01312961
—Trial running · NCT06488755
OCS dose reduction70.1% vs 41.9%+28.2 vs placebo300 mg q2w · wk 24 · n 103NCT02528214
1 other result
  • 100% vs 50% 300 mg q2w · wk 24 · n 101 · Phase 3 · primary NCT02528214
—Trial running · NCT06488755

Severe exacerbations, annualised rate

dupilumab
0.5 vs 1.0−0.4 vs placebo300 mg q2w · wk 52 · n 633NCT02414854
7 other results
  • 0.5 vs 1.0 200 mg q2w · wk 52 · n 631 · Phase 3 · primary NCT02414854
  • 0.6 vs 1.6 300 mg q2w · wk 24 · n 103 · Phase 3 · secondary NCT02528214
  • 0.5 vs 0.1 wk 52 · n 13 · Phase 3 · secondary NCT03560466
  • 0.3 vs 0.9 300 mg q2w · wk 24 · n 156 · Phase 2 · secondary NCT01854047
  • 0.3 vs 0.9 200 mg q2w · wk 24 · n 148 · Phase 2 · secondary NCT01854047
  • 0.6 vs 0.9 300 mg q4w · wk 24 · n 157 · Phase 2 · secondary NCT01854047
  • 0.4 vs 0.9 200 mg q4w · wk 24 · n 150 · Phase 2 · secondary NCT01854047
Rademikibart
—Trial running · NCT06488755

Trough FEV1, change

dupilumab
0.3 vs 0.7−0.4 vs placebowk 64 · n 13NCT03560466
5 other results
  • 0.3 vs 0.6 wk 52 · n 13 · Phase 3 · secondary NCT03560466
  • 0.1 vs 0.5 wk 24 · n 13 · Phase 3 · secondary NCT03560466
  • 0.2 vs 0.4 wk 12 · n 13 · Phase 3 · secondary NCT03560466
  • 0.1 vs 0.4 wk 8 · n 13 · Phase 3 · secondary NCT03560466
  • 0.1 vs 0.4 wk 2 · n 13 · Phase 3 · secondary NCT03560466
Rademikibart
—Trial running · NCT06488755

ACQ-5, change

dupilumab
-1.5 vs -1.3−0.2 vs placebo300 mg q2w · wk 52 · n 633NCT02414854
19 other results
  • -1.5 vs -1.2 300 mg q2w · wk 36 · n 633 · Phase 3 · secondary NCT02414854
  • -1.4 vs -1.1 300 mg q2w · wk 12 · n 633 · Phase 3 · secondary NCT02414854
  • -1.2 vs -1.1 300 mg q2w · wk 8 · n 633 · Phase 3 · secondary NCT02414854
  • -1.1 vs -0.8 300 mg q2w · wk 4 · n 633 · Phase 3 · secondary NCT02414854
  • -0.9 vs -0.6 300 mg q2w · wk 2 · n 633 · Phase 3 · secondary NCT02414854
  • -1.5 vs -1.3 200 mg q2w · wk 52 · n 631 · Phase 3 · secondary NCT02414854
  • -1.5 vs -1.2 200 mg q2w · wk 36 · n 631 · Phase 3 · secondary NCT02414854
  • -1.3 vs -1.1 200 mg q2w · wk 12 · n 631 · Phase 3 · secondary NCT02414854
  • -1.3 vs -1.1 200 mg q2w · wk 8 · n 631 · Phase 3 · secondary NCT02414854
  • -1.1 vs -0.8 200 mg q2w · wk 4 · n 631 · Phase 3 · secondary NCT02414854
  • -0.9 vs -0.6 200 mg q2w · wk 2 · n 631 · Phase 3 · secondary NCT02414854
  • -0.9 vs -0.6 300 mg q2w · wk 24 · n 103 · Phase 3 · secondary NCT02528214
  • -0.8 vs -0.5 300 mg q2w · wk 20 · n 103 · Phase 3 · secondary NCT02528214
  • -0.9 vs -0.6 300 mg q2w · wk 16 · n 103 · Phase 3 · secondary NCT02528214
  • -0.9 vs -0.5 300 mg q2w · wk 12 · n 103 · Phase 3 · secondary NCT02528214
  • -0.7 vs -0.4 300 mg q2w · wk 8 · n 103 · Phase 3 · secondary NCT02528214
  • -0.6 vs -0.4 300 mg q2w · wk 4 · n 103 · Phase 3 · secondary NCT02528214
  • -0.5 vs -0.2 300 mg q2w · wk 2 · n 103 · Phase 3 · secondary NCT02528214
  • -1.1 vs -0.5 300 mg qw · wk 12 · n 44 · Phase 2 · secondary NCT01312961
Rademikibart
—Trial running · NCT06488755

OCS dose reduction

dupilumab
70.1% vs 41.9%+28.2 vs placebo300 mg q2w · wk 24 · n 103NCT02528214
1 other result
  • 100% vs 50% 300 mg q2w · wk 24 · n 101 · Phase 3 · primary NCT02528214
Rademikibart
—Trial running · NCT06488755
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Rademikibart: no structured comparison results are available for Asthma.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. dupilumab: 4 of 4 rows · Rademikibart: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricdupilumab
Dropout rate
7.7%a
NCT03560466 · Phase 3 · background therapy
show 36 more results
—Participants From DRI12544 Study D
NCT02134028 · Phase 3
—Participants From DRI12544 Study P
NCT02134028 · Phase 3
10%Participants From DRI12544: Dupilu
NCT02134028 · Phase 3
8.1%Participants From DRI12544: Placeb
NCT02134028 · Phase 3
—Participants From EFC13579 Study D
NCT02134028 · Phase 3
—Participants From EFC13579 Study P
NCT02134028 · Phase 3
10.4%Participants From EFC13579: Dupilu
NCT02134028 · Phase 3
10.1%Participants From EFC13579: Placeb
NCT02134028 · Phase 3
—Participants From EFC13691 Study D
NCT02134028 · Phase 3
—Participants From EFC13691 Study P
NCT02134028 · Phase 3
15.6%Participants From EFC13691: Dupilu
NCT02134028 · Phase 3
14.4%Participants From EFC13691: Placeb
NCT02134028 · Phase 3
—Participants From PDY14192 Study D
NCT02134028 · Phase 3
—Participants From PDY14192 Study P
NCT02134028 · Phase 3
21.4%Participants From PDY14192: Dupilu
NCT02134028 · Phase 3
21.1%Participants From PDY14192: Placeb
NCT02134028 · Phase 3
5.1%300 mg q2w
NCT01854047 · Phase 2
8.7%200 mg q2w
NCT01854047 · Phase 2
9.6%300 mg q4w
NCT01854047 · Phase 2
12.3%200 mg q4w
NCT01854047 · Phase 2
8.1%300 mg q2w
NCT02414854 · Phase 3
7.1%200 mg q2w
NCT02414854 · Phase 3
2.9%300 mg q2w
NCT02528214 · Phase 3
—300mg q2w
NCT02528214 · Phase 3
3.9%300 mg Q2W
NCT04998604 · Phase 4 · registry result, not featured evidence
5.9%200 mg Q2W
NCT04502862 · Phase 4 · registry result, not featured evidence
2.8%300 mg Q2W
NCT04400318 · Phase 4 · registry result, not featured evidence
—300 mg Q2W
NCT04203797 · Phase 4 · registry result, not featured evidence
0%Dupilumab
NCT04203797 · Phase 4 · registry result, not featured evidence
0%
NCT05036733 · Phase 4 · registry result, not featured evidence
4.8%
NCT03620747 · Phase 3 · registry result, not featured evidence
25.3%300 mg
NCT03387852 · Phase 2 · registry result, not featured evidence
—300mg
NCT03387852 · Phase 2 · registry result, not featured evidence
36.5%SAR440340 + Dupilumab
NCT03387852 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02573233 · Phase 2 · registry result, not featured evidence
13.5%300 mg qw
NCT01312961 · Phase 2 · registry result, not featured evidence · background therapy
Discontinued due to AEs
0%a
NCT03560466 · Phase 3 · background therapy
show 36 more results
—Participants From DRI12544 Study D
NCT02134028 · Phase 3
—Participants From DRI12544 Study P
NCT02134028 · Phase 3
4.5%Participants From DRI12544: Dupilu
NCT02134028 · Phase 3
2.7%Participants From DRI12544: Placeb
NCT02134028 · Phase 3
—Participants From EFC13579 Study D
NCT02134028 · Phase 3
—Participants From EFC13579 Study P
NCT02134028 · Phase 3
3.2%Participants From EFC13579: Dupilu
NCT02134028 · Phase 3
2.5%Participants From EFC13579: Placeb
NCT02134028 · Phase 3
—Participants From EFC13691 Study D
NCT02134028 · Phase 3
—Participants From EFC13691 Study P
NCT02134028 · Phase 3
5.6%Participants From EFC13691: Dupilu
NCT02134028 · Phase 3
4.1%Participants From EFC13691: Placeb
NCT02134028 · Phase 3
—Participants From PDY14192 Study D
NCT02134028 · Phase 3
—Participants From PDY14192 Study P
NCT02134028 · Phase 3
14.3%Participants From PDY14192: Dupilu
NCT02134028 · Phase 3
5.3%Participants From PDY14192: Placeb
NCT02134028 · Phase 3
2.5%300 mg q2w
NCT01854047 · Phase 2
4%200 mg q2w
NCT01854047 · Phase 2
6.4%300 mg q4w
NCT01854047 · Phase 2
4.5%200 mg q4w
NCT01854047 · Phase 2
1.9%300 mg q2w
NCT02414854 · Phase 3
1.1%200 mg q2w
NCT02414854 · Phase 3
1%300 mg q2w
NCT02528214 · Phase 3
—300mg q2w
NCT02528214 · Phase 3
1.7%300 mg Q2W
NCT04998604 · Phase 4 · registry result, not featured evidence
1%200 mg Q2W
NCT04502862 · Phase 4 · registry result, not featured evidence
1.4%300 mg Q2W
NCT04400318 · Phase 4 · registry result, not featured evidence
—300 mg Q2W
NCT04203797 · Phase 4 · registry result, not featured evidence
0%Dupilumab
NCT04203797 · Phase 4 · registry result, not featured evidence
—
NCT05036733 · Phase 4 · registry result, not featured evidence
1.5%
NCT03620747 · Phase 3 · registry result, not featured evidence
0%300 mg
NCT03387852 · Phase 2 · registry result, not featured evidence
—300mg
NCT03387852 · Phase 2 · registry result, not featured evidence
2.7%SAR440340 + Dupilumab
NCT03387852 · Phase 2 · registry result, not featured evidence · combination
—
NCT02573233 · Phase 2 · registry result, not featured evidence
5.8%300 mg qw
NCT01312961 · Phase 2 · registry result, not featured evidence · background therapy
Serious AEs
30.8%a
NCT03560466 · Phase 3 · background therapy
show 36 more results
10%Participants From DRI12544 Study D
NCT02134028 · Phase 3
12.6%Participants From DRI12544 Study P
NCT02134028 · Phase 3
—Participants From DRI12544: Dupilu
NCT02134028 · Phase 3
—Participants From DRI12544: Placeb
NCT02134028 · Phase 3
10.5%Participants From EFC13579 Study D
NCT02134028 · Phase 3
9.3%Participants From EFC13579 Study P
NCT02134028 · Phase 3
—Participants From EFC13579: Dupilu
NCT02134028 · Phase 3
—Participants From EFC13579: Placeb
NCT02134028 · Phase 3
11.1%Participants From EFC13691 Study D
NCT02134028 · Phase 3
12.4%Participants From EFC13691 Study P
NCT02134028 · Phase 3
—Participants From EFC13691: Dupilu
NCT02134028 · Phase 3
—Participants From EFC13691: Placeb
NCT02134028 · Phase 3
28.6%Participants From PDY14192 Study D
NCT02134028 · Phase 3
0%Participants From PDY14192 Study P
NCT02134028 · Phase 3
—Participants From PDY14192: Dupilu
NCT02134028 · Phase 3
—Participants From PDY14192: Placeb
NCT02134028 · Phase 3
8.3%300 mg q2w
NCT01854047 · Phase 2
6.8%200 mg q2w
NCT01854047 · Phase 2
10.2%300 mg q4w
NCT01854047 · Phase 2
4%200 mg q4w
NCT01854047 · Phase 2
8.9%300 mg q2w
NCT02414854 · Phase 3
8.1%200 mg q2w
NCT02414854 · Phase 3
—300 mg q2w
NCT02528214 · Phase 3
8.7%300mg q2w
NCT02528214 · Phase 3
1.7%300 mg Q2W
NCT04998604 · Phase 4 · registry result, not featured evidence
3%200 mg Q2W
NCT04502862 · Phase 4 · registry result, not featured evidence
4.2%300 mg Q2W
NCT04400318 · Phase 4 · registry result, not featured evidence
0%300 mg Q2W
NCT04203797 · Phase 4 · registry result, not featured evidence
—Dupilumab
NCT04203797 · Phase 4 · registry result, not featured evidence
13.3%
NCT05036733 · Phase 4 · registry result, not featured evidence
5.6%
NCT03620747 · Phase 3 · registry result, not featured evidence
—300 mg
NCT03387852 · Phase 2 · registry result, not featured evidence
4.1%300mg
NCT03387852 · Phase 2 · registry result, not featured evidence
2.7%SAR440340 + Dupilumab
NCT03387852 · Phase 2 · registry result, not featured evidence · combination
5%
NCT02573233 · Phase 2 · registry result, not featured evidence
1.9%300 mg qw
NCT01312961 · Phase 2 · registry result, not featured evidence · background therapy
Most frequent reported AEs
a
pyrexia 46.2% (placebo 2.4%)
influenza 38.5% (placebo 5.6%)
nasopharyngitis 38.5% (placebo 9.6%)
NCT03560466 · Phase 3 · background therapy
show 24 more results
nasopharyngitis 25.9%
bronchitis 19%
upper respiratory tract infection 14.3%
NCT02134028 · Phase 3
nasopharyngitis 24.3%
injection site erythema 23.4%
upper respiratory tract infection 16.2%
NCT02134028 · Phase 3
nasopharyngitis 18.9%
upper respiratory tract infection 12.8%
bronchitis 11.5%
NCT02134028 · Phase 3
nasopharyngitis 19.1%
upper respiratory tract infection 12.6%
bronchitis 12.2%
NCT02134028 · Phase 3
nasopharyngitis 17.8%
bronchitis 15.6%
influenza 7.8%
NCT02134028 · Phase 3
nasopharyngitis 17.5%
bronchitis 9.3%
influenza 9.3%
NCT02134028 · Phase 3
injection site erythema 42.9%
nasopharyngitis 42.9%
back pain 21.4%
NCT02134028 · Phase 3
injection site erythema 42.1%
headache 21.1%
vomiting 21.1%
NCT02134028 · Phase 3
300 mg q2w
injection site erythema 21.8% (placebo 7.6%)
upper respiratory tract infection 12.8% (placebo 17.7%)
bronchitis 12.2% (placebo 10.1%)
NCT01854047 · Phase 2
200 mg q2w
upper respiratory tract infection 14.9% (placebo 17.7%)
injection site erythema 14.2% (placebo 7.6%)
headache 11.5% (placebo 12.7%)
NCT01854047 · Phase 2
300 mg q4w
headache 12.1% (placebo 12.7%)
nasopharyngitis 12.1% (placebo 9.5%)
upper respiratory tract infection 12.1% (placebo 17.7%)
NCT01854047 · Phase 2
200 mg q4w
upper respiratory tract infection 14.7% (placebo 17.7%)
injection site erythema 8.7% (placebo 7.6%)
sinusitis 8% (placebo 7%)
NCT01854047 · Phase 2
300 mg q2w
viral upper respiratory tract infection 17.7% (placebo 19.2%)
injection site erythema 15.5% (placebo 4.2%)
upper respiratory tract infection 12.2% (placebo 11.8%)
NCT02414854 · Phase 3
200 mg q2w
viral upper respiratory tract infection 19.2% (placebo 19.2%)
injection site erythema 12% (placebo 4.2%)
bronchitis 11.6% (placebo 15%)
NCT02414854 · Phase 3
300mg q2w
viral upper respiratory tract infection 8.7% (placebo 17.8%)
bronchitis 6.8% (placebo 5.6%)
eosinophil count increased 6.8% (placebo 0%)
NCT02528214 · Phase 3
300 mg Q2W
nasopharyngitis 11.7%
accidental overdose 6.7%
headache 5.6%
NCT04998604 · Phase 4 · registry result, not featured evidence
200 mg Q2W
asthma 9% (placebo 13.9%)
nasopharyngitis 4% (placebo 6.9%)
NCT04502862 · Phase 4 · registry result, not featured evidence
300 mg Q2W
covid-19 9.7% (placebo 8.1%)
headache 6.9% (placebo 8.1%)
asthma 5.6% (placebo 24.3%)
NCT04400318 · Phase 4 · registry result, not featured evidence
300 mg Q2W
asthma 5% (placebo 10%)
cough 5% (placebo 5%)
immunisation reaction 5% (placebo 0%)
NCT04203797 · Phase 4 · registry result, not featured evidence
asthma 13.2%
nasopharyngitis 8.4%
covid-19 5.6%
NCT03620747 · Phase 3 · registry result, not featured evidence
300mg
headache 13.5% (placebo 9.5%)
nasopharyngitis 12.2% (placebo 12.2%)
rhinitis allergic 6.8% (placebo 1.4%)
NCT03387852 · Phase 2 · registry result, not featured evidence
nasopharyngitis 10.8% (placebo 12.2%)
headache 6.8% (placebo 9.5%)
injection site reaction 6.8% (placebo 5.4%)
NCT03387852 · Phase 2 · registry result, not featured evidence · combination
headache 25% (placebo 13.6%)
back pain 15% (placebo 0%)
injection site erythema 15% (placebo 9.1%)
NCT02573233 · Phase 2 · registry result, not featured evidence
300 mg qw
nasopharyngitis 13.5% (placebo 3.8%)
upper respiratory tract infection 13.5% (placebo 17.3%)
headache 11.5% (placebo 5.8%)
NCT01312961 · Phase 2 · registry result, not featured evidence · background therapy

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

dupilumab

FEV1% Predicted 7.08% (n=13) @ 12wk
absolute change · percentage points
No placebo or comparator arm
NCT03560466 · Phase 3 · background therapy
show 1 more result
7% (n=13) @ 4wk
NCT03560466 · Phase 3 · background therapy
Severe Exacerbation Rate Annualized 0.265 vs 0.897 placebo per year @ 24wk300 mg q2w
event rate · per year
NCT01854047 · Phase 2
show 7 more results
0.524 vs 0.871 placebo per year @ 52wk300 mg q2w
NCT02414854 · Phase 3
0.649 vs 1.597 placebo per year @ 24wk300 mg q2w
NCT02528214 · Phase 3
0.269 vs 0.897 placebo per year @ 24wk200 mg q2w
NCT01854047 · Phase 2
0.456 vs 0.871 placebo per year @ 52wk200 mg q2w
NCT02414854 · Phase 3
0.599 vs 0.897 placebo per year @ 24wk300 mg q4w
NCT01854047 · Phase 2
0.415 vs 0.897 placebo per year @ 24wk200 mg q4w
NCT01854047 · Phase 2
0.462 vs 0.114 placebo per year @ 52wk
NCT03560466 · Phase 3 · background therapy
FEV1% Predicted 8.44% (n=633) vs 2.58% (n=317) placebo @ 2wk300 mg q2w
absolute change · percentage points
NCT02414854 · Phase 3
show 19 more results
9.2% (n=633) vs 4.55% (n=317) placebo @ 4wk300 mg q2w
NCT02414854 · Phase 3
9.7% (n=633) vs 4.93% (n=317) placebo @ 8wk300 mg q2w
NCT02414854 · Phase 3
10.28% (n=633) vs 5.02% (n=317) placebo @ 12wk300 mg q2w
NCT02414854 · Phase 3
10.14% (n=633) vs 4.38% (n=317) placebo @ 24wk300 mg q2w
NCT02414854 · Phase 3
10.94% (n=633) vs 5.09% (n=317) placebo @ 36wk300 mg q2w
NCT02414854 · Phase 3
11.02% (n=633) vs 4.25% (n=317) placebo @ 52wk300 mg q2w
NCT02414854 · Phase 3
7.1% (n=631) vs 2.58% (n=317) placebo @ 2wk200 mg q2w
NCT02414854 · Phase 3
7.92% (n=631) vs 4.55% (n=317) placebo @ 4wk200 mg q2w
NCT02414854 · Phase 3
9.27% (n=631) vs 4.93% (n=317) placebo @ 8wk200 mg q2w
NCT02414854 · Phase 3
9.22% (n=631) vs 5.02% (n=317) placebo @ 12wk200 mg q2w
NCT02414854 · Phase 3
9.98% (n=631) vs 4.38% (n=317) placebo @ 24wk200 mg q2w
NCT02414854 · Phase 3
10.12% (n=631) vs 5.09% (n=317) placebo @ 36wk200 mg q2w
NCT02414854 · Phase 3
10.08% (n=631) vs 4.25% (n=317) placebo @ 52wk200 mg q2w
NCT02414854 · Phase 3
7.5% (n=13) vs 8.06% (n=122) placebo @ 2wk
NCT03560466 · Phase 3 · background therapy
6.31% (n=13) vs 7.93% (n=122) placebo @ 8wk
NCT03560466 · Phase 3 · background therapy
7.08% (n=13) vs 8.31% (n=122) placebo @ 12wk
NCT03560466 · Phase 3 · background therapy
4.08% (n=13) vs 8.37% (n=122) placebo @ 24wk
NCT03560466 · Phase 3 · background therapy
6.73% (n=13) vs 8.81% (n=122) placebo @ 52wk
NCT03560466 · Phase 3 · background therapy
1.17% (n=13) vs 7.98% (n=122) placebo @ 64wk
NCT03560466 · Phase 3 · background therapy
FEV1 Trough 0.13 vs 0.36 placebo L @ 2wk
absolute change · L
NCT03560466 · Phase 3 · background therapy
show 5 more results
0.12 vs 0.38 placebo L @ 8wk
NCT03560466 · Phase 3 · background therapy
0.17 vs 0.41 placebo L @ 12wk
NCT03560466 · Phase 3 · background therapy
0.15 vs 0.46 placebo L @ 24wk
NCT03560466 · Phase 3 · background therapy
0.34 vs 0.62 placebo L @ 52wk
NCT03560466 · Phase 3 · background therapy
0.25 vs 0.66 placebo L @ 64wk
NCT03560466 · Phase 3 · background therapy
FEV1 Trough 0.13 L @ 4wk
absolute change · L
No placebo or comparator arm
NCT03560466 · Phase 3 · background therapy
FVC 0.25 vs 0.08 placebo L @ 2wk300 mg q2w
absolute change · L
NCT02414854 · Phase 3
show 19 more results
0.27 vs 0.12 placebo L @ 4wk300 mg q2w
NCT02414854 · Phase 3
0.29 vs 0.13 placebo L @ 8wk300 mg q2w
NCT02414854 · Phase 3
0.29 vs 0.13 placebo L @ 12wk300 mg q2w
NCT02414854 · Phase 3
0.29 vs 0.11 placebo L @ 24wk300 mg q2w
NCT02414854 · Phase 3
0.31 vs 0.11 placebo L @ 36wk300 mg q2w
NCT02414854 · Phase 3
0.31 vs 0.08 placebo L @ 52wk300 mg q2w
NCT02414854 · Phase 3
0.23 vs 0.08 placebo L @ 2wk200 mg q2w
NCT02414854 · Phase 3
0.26 vs 0.12 placebo L @ 4wk200 mg q2w
NCT02414854 · Phase 3
0.28 vs 0.13 placebo L @ 8wk200 mg q2w
NCT02414854 · Phase 3
0.29 vs 0.13 placebo L @ 12wk200 mg q2w
NCT02414854 · Phase 3
0.29 vs 0.11 placebo L @ 24wk200 mg q2w
NCT02414854 · Phase 3
0.3 vs 0.11 placebo L @ 36wk200 mg q2w
NCT02414854 · Phase 3
0.29 vs 0.08 placebo L @ 52wk200 mg q2w
NCT02414854 · Phase 3
0.11 vs 0.35 placebo L @ 2wk
NCT03560466 · Phase 3 · background therapy
0.11 vs 0.37 placebo L @ 8wk
NCT03560466 · Phase 3 · background therapy
0.12 vs 0.4 placebo L @ 12wk
NCT03560466 · Phase 3 · background therapy
0.17 vs 0.47 placebo L @ 24wk
NCT03560466 · Phase 3 · background therapy
0.36 vs 0.68 placebo L @ 52wk
NCT03560466 · Phase 3 · background therapy
0.41 vs 0.74 placebo L @ 64wk
NCT03560466 · Phase 3 · background therapy
FVC 0.09 L @ 4wk
absolute change · L
No placebo or comparator arm
NCT03560466 · Phase 3 · background therapy
FEF 25-75% 0.27 vs 0.09 placebo L @ 2wk300 mg q2w
absolute change · L
NCT02414854 · Phase 3
show 19 more results
0.29 vs 0.16 placebo L @ 4wk300 mg q2w
NCT02414854 · Phase 3
0.32 vs 0.18 placebo L @ 8wk300 mg q2w
NCT02414854 · Phase 3
0.35 vs 0.18 placebo L @ 12wk300 mg q2w
NCT02414854 · Phase 3
0.35 vs 0.17 placebo L @ 24wk300 mg q2w
NCT02414854 · Phase 3
0.36 vs 0.18 placebo L @ 36wk300 mg q2w
NCT02414854 · Phase 3
0.36 vs 0.16 placebo L @ 52wk300 mg q2w
NCT02414854 · Phase 3
0.22 vs 0.09 placebo L @ 2wk200 mg q2w
NCT02414854 · Phase 3
0.24 vs 0.16 placebo L @ 4wk200 mg q2w
NCT02414854 · Phase 3
0.29 vs 0.18 placebo L @ 8wk200 mg q2w
NCT02414854 · Phase 3
0.3 vs 0.18 placebo L @ 12wk200 mg q2w
NCT02414854 · Phase 3
0.34 vs 0.17 placebo L @ 24wk200 mg q2w
NCT02414854 · Phase 3
0.35 vs 0.18 placebo L @ 36wk200 mg q2w
NCT02414854 · Phase 3
0.36 vs 0.16 placebo L @ 52wk200 mg q2w
NCT02414854 · Phase 3
0.21 vs 0.49 placebo L @ 2wk
NCT03560466 · Phase 3 · background therapy
0.15 vs 0.48 placebo L @ 8wk
NCT03560466 · Phase 3 · background therapy
0.29 vs 0.54 placebo L @ 12wk
NCT03560466 · Phase 3 · background therapy
0.15 vs 0.58 placebo L @ 24wk
NCT03560466 · Phase 3 · background therapy
0.4 vs 0.73 placebo L @ 52wk
NCT03560466 · Phase 3 · background therapy
0.11 vs 0.77 placebo L @ 64wk
NCT03560466 · Phase 3 · background therapy
FEF 25-75% 0.25 L @ 4wk
absolute change · L
No placebo or comparator arm
NCT03560466 · Phase 3 · background therapy
ACQ-7 -0.65 score @ 2wk
absolute change · score
No placebo or comparator arm
NCT03560466 · Phase 3 · background therapy
show 7 more results
-0.68 score @ 4wk
NCT03560466 · Phase 3 · background therapy
-0.84 score @ 8wk
NCT03560466 · Phase 3 · background therapy
-1.03 score @ 12wk
NCT03560466 · Phase 3 · background therapy
-0.96 score @ 24wk
NCT03560466 · Phase 3 · background therapy
-1.01 score @ 36wk
NCT03560466 · Phase 3 · background therapy
-1.21 score @ 52wk
NCT03560466 · Phase 3 · background therapy
-0.99 score @ 64wk
NCT03560466 · Phase 3 · background therapy
ACQ-5 -0.68 score @ 2wk
absolute change · score
No placebo or comparator arm
NCT03560466 · Phase 3 · background therapy
show 7 more results
-0.75 score @ 4wk
NCT03560466 · Phase 3 · background therapy
-0.92 score @ 8wk
NCT03560466 · Phase 3 · background therapy
-1.2 score @ 12wk
NCT03560466 · Phase 3 · background therapy
-1.15 score @ 24wk
NCT03560466 · Phase 3 · background therapy
-1.25 score @ 36wk
NCT03560466 · Phase 3 · background therapy
-1.49 score @ 52wk
NCT03560466 · Phase 3 · background therapy
-1.28 score @ 64wk
NCT03560466 · Phase 3 · background therapy
Severe Exacerbation Rate Annualized 0.314 per year
event rate · per year
No placebo or comparator arm
NCT02134028 · Phase 3
show 7 more results
0.33 per year
NCT02134028 · Phase 3
0.351 per year
NCT02134028 · Phase 3
0.331 per year
NCT02134028 · Phase 3
0.302 per year
NCT02134028 · Phase 3
0.391 per year
NCT02134028 · Phase 3
0.149 per year
NCT02134028 · Phase 3
0.077 per year
NCT02134028 · Phase 3

+ 111 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dupilumab's landscape · Rademikibart's landscape